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ABSTRACT   
Experimental Techniques for the Isolation of Pancreatic Stellate Cells    Mehdi Jalali 
Background: Two decades ago the pancreatic stellate cell (PSC) was identified as the cell 
type predominantly responsible for the ‘desmoplastic reaction’ associated with pancreatic 
cancer.  PSCs have since been found to exhibit a great deal of interaction with cancer cells in 
vitro and in vivo. This feature, combined with their contribution to the stromal reaction, 
makes PSCs fundamental to pancreatic cancer progression. Understanding the mechanisms 
which mediate the transformation of stellate cells from their non proliferative quiescent state, 
to their tumour promoting activated state is vital, since inactivation of stellate cells in 
pancreatic tumours should reduce the mass of fibrotic tissue in and around the tumour, and 
enable better delivery of chemotherapeutic agents.   
Methods: Attempts were made to isolate PSCs from pathological human pancreatic tissue 
using an ‘explant’ method.  Cells which grew from the tissue were propagated and 
characterised according to morphology and the fluorescent expression of stellate cell 
markers: alpha SMA, GFAP, desmin, vimentin.  
Results: Primary cells were isolated from 10 patients who possessed a variety of pancreatic 
diseases.  Characterisation revealed three distinct cell types, one of which most closely 
resembled the PSC due to its morphology and expression of cell markers.  However, several 
difficulties encountered during characterisation, particularly the lack of suitable cell controls, 
meant that it was not possible to identify these primary cells as PSCs.  
Alpha SMA and GFAP were expressed in the primary cells, and antibody binding was 
specific according to isotype control stains.  Unfortunately, the immortalised PSCs that were 
utilised as a positive cell control failed to exhibit alpha SMA.  Furthermore, numerous 
epithelial cancer cell lines unexpectedly expressed GFAP, desmin, and vimentin.  Around 
eighty flasks of primary cells were cryopreserved for use in future experiments.  Two of the 
primary cell samples, along with the immortalised PSC line were taken forward for 
preliminary investigations of microRNA-29 expression.  However, this yielded inconclusive 
data.   
Discussion:  A subsequent literature search revealed several studies which also demonstrated 
the mesenchymal characteristics of epithelial cancer cells.  This suggests that specific binding 
may well have taken place in our experiments. As a result of the work described in this thesis, 
viii 
 
there are now stocks of tumour derived- and inflammatory derived primary pancreatic cells, 
which following complete characterisation, will be ready to be utilised as an adjunct to the 
epithelial cancer cell lines frequently used for pancreatic cancer research in this laboratory.   
 
 
  
 
 
 
 
 
  
ix 
 
ACKNOWLEDGEMENTS 
 
I firstly wish to thank my supervisors Dr Eithne Costello-Goldring, Reader in Molecular 
Biology, and Dr Bill Greenhalf, Senior Lecturer in Molecular Biology, University of 
Liverpool, for their help and guidance throughout this degree.   
I am very grateful to Dr Fiona Campbell, Department of Pathology, for dissecting pancreatic 
tissue samples for my primary cell culture, and also for providing H/E photographs which are 
displayed later on in this thesis.  I would also like to thank Dr Margaret Roebuck for sharing 
her expertise regarding primary cell culture. 
I am also grateful to the post-doctoral researchers within the Department of Molecular and 
Clinical Cancer Medicine, in particular Dr Claire Jenkinson for her advice throughout the 
year, as well as the other postgraduate research students for their help in teaching me various 
laboratory techniques, including Mr Paul Sykes for showing me how to carry out 
Immunofluorescence microscopy. 
Finally, I have to thank the Royal College of Surgeons of England and the Jean Shanks 
Foundation for providing me with the necessary funds to undertake this postgraduate degree. 
  
x 
 
LIST OF ABBREVIATIONS 
Bone marrow         BM 
Bovine serum albumin       BSA 
Bromodeoxyuridine        BrdU 
Common bile duct        CBD 
Complementary DNA        cDNA 
Connective tissue growth factor      CTGF 
Crossing point         Cp 
Dulbecco’s modified Eagle medium      DMEM 
Dimethyl Sulfoxide        DMSO 
Epidermal growth factor       EGF 
Epithelial to mesenchymal transition      EMT 
Ethylenediaminetetraacetic acid      EDTA 
Extracellular matrix        ECM 
Extracellular matrix metalloproteinase inducer    EMMPRIN 
Endoscopic retrograde cholangiopancreatography    ERCP 
Basic fibroblast growth factor      FGF2 
Foetal bovine serum        FBS 
Familial Pancreatic Cancer       FPC 
Good clinical laboratory practice      GCLP 
Glial Fibrillary Acidic Protein      GFAP 
Head of pancreas        HOP 
Hepatic stellate cell        HSC 
Immunofluorescence        IF 
Interleukin         IL 
Iscove’s modified Dulbecco’s medium     IMDM 
Laboratory information management system     LIMS 
Liverpool Experimental Cancer Medicine Centre    LECMC 
Major histocompatibility complex      MHC 
xi 
 
MicroRNA         miRNA 
Millilitre         mL 
Messenger RNA        mRNA 
Monocyte chemoattractant protein 1      MCP-1 
Magnetic resonance cholangiopancreatography    MRCP 
Neuropilin-1         NRP-1 
Nucleotide         nt 
Pancreatic intraepithelial lesion      PanIN 
Pancreatic ductal adenocarcinoma      PDAC 
Pancreatic stellate cell       PSC  
Protease activated receptor-2       PAR-2 
Phosphate buffered saline       PBS 
Platelet derived growth factor       PDGF 
Precursor microRNA        pre-miRNA 
Primary microRNA        pri-miRNA 
Randomised Controlled Trial       RCT 
Reactive oxygen species       ROS 
Roswell Park Memorial Institute      RPMI 
Royal Liverpool University Hospital      RLUH 
Smooth muscle actin        SMA 
Secreted protein acidic and rich in cysteine     SPARC 
Standard operating procedure       SOP 
Transforming growth factor beta      TGFβ 
Tumour necrosis factor alpha       TNFα 
Terminal deoxynucleotidyl transferase dUTP nick end labelling  TUNEL 
Urokinase-type plasminogen activator     uPA 
Tissue plasminogen activator       tPA 
Vascular endothelial growth factor      VEGF 
Vascular endothelial growth factor receptor     VEGF-R
1 
 
 
 
 
 
 
 
CHAPTER 1: 
INTRODUCTION 
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1.1 Anatomy and Physiology of the Pancreas 
 
The pancreas is a retroperitoneal organ, approximately 15 cm in length.  It can be 
anatomically split into the head, neck, body and tail 
1
.  The head, which contributes to around 
half the mass of the organ, is embraced on its right side by the C-shaped curve of the 
duodenum 
2
.  The neck is a slight constriction which connects the head to the body of the 
pancreas 
4
.  The body gradually tapers to form a tail, which lies in close proximity to the left 
colic flexure of the colon and the splenic hilum 
1
.   
The postero-inferior surface of the stomach rests upon the anterior surface of the pancreas 
body, and the two organs are separated by omental bursa 
2
.  The pancreas body is devoid of 
peritoneum on its posterior side, and the aorta, superior mesentery artery, and left kidney are 
in close proximity.  Lienal and pancreaticoduodenal branches of the hepatic and superior 
mesenteric arteries supply blood to the pancreas, and lienal and superior mesenteric veins 
drain the pancreas 
4
. 
The cells which populate the pancreas can be split into two main histological cell types:  
exocrine and endocrine cells.  The exocrine portion of the organ is involved in digestion and 
consists of a network of ducts, which at their terminal end expand into sac-like structures 
called acini 
5
.  These ducts carry a fluid consisting of proenzymes and bicarbonate solution 
called pancreatic juice towards the ampulla of Vater for entry into the duodenum.  The 
endocrine cells group together within the exocrine tissue to make up the Islets of Langerhans, 
and these cells play a major role in sugar metabolism 
6
. 
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1.2 Pancreatic cancer 
  
Pancreatic cancer is a highly aggressive disease, representing the most lethal type of digestive 
cancer and the fourth leading cause of cancer-related mortality in the developed world 
7;8
.  Its 
poor prognosis is epitomised by a 5 year survival of less than 5%.  The poor prognosis is 
somewhat related to the anatomical site, by which patients tend to develop symptoms late on 
in the course of the disease, already having developed locally advanced or metastatic disease 
at the time of presentation 
9
.   
 
 
1.2.1 Epidemiology 
 
The cause of pancreatic cancer remains unknown although several risk factors have been 
implicated including smoking, a family history, advanced age, male gender, chronic 
pancreatitis, diabetes mellitus, and a diet high in meats and low in vegetables.  The dominant 
risk factors that have been studied are smoking and family history.  Resected pancreatic 
cancers from patients who smoke contain more genetic mutations than those from non-
smokers 
10
, and the risk of pancreatic cancer in smokers is 2.5 to 3.6 times greater than that in 
non-smokers.  This risk is dose dependent according to the amount of tobacco use and the 
length of time exposed to tobacco smoke 
9
.          
Approximately, 7 to 10% of sufferers have a positive family history of pancreatic cancer and 
are diagnosed with familial pancreatic cancer (FPC) 
11
.  FPC is inherited in an autosomal 
dominant fashion, and can be defined as a family which harbours at least two first-degree 
relatives that have been diagnosed with pancreatic cancer 
12
.  A person who has one first 
degree-relative with pancreatic cancer is reported to be 9 times more likely to develop the 
disease 
11
.  The risk of getting FPC is over 50 times as high in families with 4 or more 
affected members in contrast to families with no affected members.  Many cases of FPC have 
been identified throughout the world, though for the majority no disease gene has been 
identified 
12
.  The most common germline mutation to cause FPC is an alteration in a DNA 
mismatch repair gene called BRCA2, where 5-20% of families with FPC harbour this 
mutation 
12;13
.   
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1.2.2 Pathogenesis of pancreatic cancer 
 
Pancreatic ductal adenocarcinoma (PDAC) accounts for over 90% of pancreatic cancers.  
Less common subtypes include mucinous cystic neoplasms, colloid carcinomas, 
adenosquamous PDAC, and neuroendocrine tumours 
4
.  Around 75% of ductal 
adenocarcinomas occur in the head of the pancreas, 15-20% occur in the body, and around 5-
10% occur in the tail of the pancreas 
8
.  Ductal adenocarcinoma of the pancreas head 
manifests as a white/yellow, firm mass which frequently expands to obstruct the adjacent 
common bile duct or main pancreatic duct.  Microscopically, these tumours vary in 
appearance according to the degree of tumour differentiation, where poorly differentiated 
tumours exhibit less gland formation and mucus production, but greater epithelial anaplasia.  
A dense fibrous matrix envelops the ductal adenocarcinoma, and surrounding tissue often 
displays regions of Chronic Pancreatitis (CP).  These areas are characterised by fibrosis, 
atrophy of glandular tissue, and dilation of ducts 
1;6
.  Infiltration of ductal adenocarcinoma 
into vascular and perineural spaces, as well as intra and peripancreatic lymph nodes, is also 
commonly viewed 
4
.    
Ductal adenocarcinoma has been proposed to evolve through several noninvasive precursor 
lesions each of which vary morphologically.  These include pancreatic intraepithelial 
neoplasia (PanIN), mucinous cystic neoplasms (MCN), and intra-ductal papillary mucinous 
neoplasms (IPMN) 
14
.   
MCNs are composed of mucin-producing epithelial cells with a distinctive ovarian-type 
stroma.  The majority contain focal areas of atypia which may eventually develop into 
carcinoma 
15
.  Compared to the other two precursor types, MCNs are the least frequent 
precursor to pancreatic cancer.  A relationship between MCN and ductal adenocarcinoma is 
based on a studies which found invasive adenocarcinoma in around one-third of resected 
MCNs, and detected common genetic mutations between the two diseases (KRAS2, TP53, 
and SMAD4) 
16;17
.  However, these studies were observational and so do not provide direct 
evidence to demonstrate the progression of MCNs to PDAC.  Furthermore, patients with 
ductal adenocarcinoma from resected MCNs have 5-year survival rates of around 60%, which 
is much higher than that associated with sporadic pancreatic cancer.  Therefore, 
adenocarcinoma from MCN should be considered separately to adenocarcinoma from 
sporadic PDAC.   
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IPMNs are large mucin-secreting neoplasms (>5 mm).  They are usually located in the 
exocrine tubes of the pancreas.  This is unlike MCNs, which are found distant from the 
pancreatic ductal system, and only occasionally communicate with it through the creation of 
erosions or fistulae 
15
.  There is similar controversy regarding the role of IPMNs as a 
precursor lesion to PDAC.  Research findings which link IPMNs to PDAC have also 
stemmed from observational studies.  These included histological and genetic analyses, with 
the latter revealing common germline mutations including KRAS2, p16, TP53, and SMAD4 
17;18
.   
The most common neoplastic precursors to invasive adenocarcinoma of the pancreas are 
PanINs.  These lesions are microscopic and so are not directly visible by pancreatic imaging.    
Molecular profiling studies have revealed a high number of common genetic alterations 
between PanINs and PDAC, including KRAS2, p16, TP53, and SMAD4 
19
.  The prevalence 
of common somatic genetic alterations increase as the amount of cytological and architectural 
atypia in PanINs increase 
11
.  Therefore, the development of PanINs can act as a useful model 
to demonstrate pancreatic cancer progression. 
PanIN development may be separated into 3 stages, beginning with ductal cell hyperplasia 
(PanIN-1A and 1B), followed by atypical hyperplasia (PanIN-2), and the formation of 
carcinoma in situ (PanIN-3) 
14
.  Low-grade PanINs (PanIN-1) are common in the elderly 
population, and PanIN-3 lesions are frequently present adjacent to PDAC on histological 
examination of resected tissue 
20
.    
    
Activation of the KRAS2 oncogene, along with telomere shortening are believed to be the 
earliest known genetic abnormalities recorded during ductal adenocarcinoma formation, and 
have been detected in PanIN-1A and 1B lesions.   The KRAS2 gene is up-regulated in over 
90% of advanced ductal adenocarcinomas resulting in subsequent atypical activation of the 
signalling pathways controlling cell proliferation and cell survival 
9
.  Telomere shortening 
has been linked to chromonsomal instability 
11
. 
CDKN2A inactivation has been noted in PanIN-2 lesions, and occurs in 95% of invasive 
ductal adenocarcinomas.  This mutation activates proliferative signalling through loss of p16, 
a protein involved in the control of the G1 to S phase transition during the cell cycle 
11;14
.  
TP53 and SMAD4 inactivation has been detected in advanced precursor lesions (PanIN-3).  
TP53 is a gene that regulates the function of DNA damage checkpoints, which usually 
6 
 
monitor the growth of regular cells.  Therefore, its down-regulation which is present in 50-
75% of pancreatic tumours results in genomic instability.  SMAD4 expression is lost in 
approximately half of pancreatic tumours, resulting in aberrant signalling by TGFβ, a growth 
factor with a multitude of roles in pancreatic cancer 
4;9
.     
Hence, almost all patients with fully established pancreatic cancer carry one or more of these 
four genetic defects.  More recently, Jones et al 
21
 performed a comprehensive genetic 
analysis of 24 early pancreatic tumours.  The results suggest that the genetic basis of 
pancreatic cancer is extremely complex and heterogeneous.  Each tumour contained an 
average of 63 genetic alterations which could be organised into a core set of 12 signalling 
pathways.  However, key mutations in each pathway varied between tumours from different 
patients, and not all tumours harboured alterations in all pathways.  
 
Somatic mutations can be utilised as molecular markers in order to observe the evolution of 
pancreatic cancers.  Studies have shown that an initial precursor neoplastic clone such as 
PanIN-1 will take more than 10 years to become malignant, and a further few years to 
metastasise.  Analysis of molecular alterations revealed that almost all of the driver genes are 
mutated by the time a primary pancreatic cancer has developed into an invasive 
adenocarcinoma.  These results highlight the potential benefit of screening patients during 
this 10 year period in which a primary cancer may reside in the pancreas before becoming 
locally invasive 
22;23
.          
 
 
1.2.3 Clinical features, diagnosis and staging 
 
As mentioned above the majority of pancreatic tumours arise in the head of the pancreas.  
When these tumours grow large enough they compress the common bile duct causing 
obstructive cholestasis, typified by jaundice, dark urine and pale stools.  General symptoms 
of pancreatic cancer include nausea, and a deep, dull abdominal pain that broadly localises to 
the tumour area, as well as systemic manifestations such as weight loss and anorexia 
9
.  Signs 
on physical examination apart from possible jaundice may include hepatomegaly, a palpable 
Virchow’s node, or palpable cervical lymph nodes 1.   
7 
 
Most people who present with symptoms attributable to pancreatic cancer have advanced 
disease, where the pancreatic tumour is typically large and has invaded beyond the confines 
of the pancreas 
1
.  One of the main reasons that pancreatic cancer has such a dismal prognosis 
is our inability to diagnose the disease at its earliest stages.  The development of a highly 
sensitive and highly specific blood based biomarker for pancreatic cancer, which could be 
used to screen individuals is the current focus of many research efforts.   
 
Currently, CA 19-9 is a biomarker used for therapeutic monitoring in pancreatic cancer, and 
early detection of recurrent disease in patients with known pancreatic cancer.  Its use as a 
screening tool has had poor results however.  Its limitations include a low specificity for 
pancreatic cancer, in that the levels of CA 19-9 may be raised in other diseases such as 
cholestasis as well 
9
.  As well as being highly sensitive and highly specific, an ideal 
biomarker for pancreatic cancer would exist in the blood at concentrations which correlate 
accurately with disease burden and response to treatment.  Moreover, it would be measurable 
using a quick, easy to use and widely available assay.  This would provide a more economical 
means of monitoring tumour burden than using standard imaging methods, thus benefiting 
the patient through reduced radiation exposure 
7
.  Screening pancreatic cancer for diagnosis 
in its early stages would not only offer potentially life-saving treatment for the patient, but 
also provide scientists with tissue samples of early stage pancreatic cancer that could be 
utilised for research.  However, the benefit of screening must be balanced against the risk of 
false diagnoses whereby healthy individuals would be subjected to major surgery 
12
. 
 
 Helical computed tomography (CT) with intravenous administration of contrast media is the 
primary investigation of choice to assess a patient in whom pancreatic cancer is suspected.  It 
can predict surgical resectability with 80 to 90% accuracy.  Alternatively, if CT fails to reveal 
a pancreatic mass, endoscopic ultrasound is also an accurate means of investigation.  It is also 
the preferred method for cytology sampling 
9
.  Endoscopic retrograde 
cholangiopancreatography (ERCP) can be used to conduct ductal brushings to aid diagnosis 
4;14
.  For patients who are unable to tolerate intravenous contrast for CT scanning, MRI can 
be used for disease staging 
11
. 
 
Pancreatic cancer staging is undertaken using the TNM classification as depicted in Table 
1.1.  Attempts can be made to resect a tumour classified as stage I or II, whereas stage III 
8 
 
tumours which have engulfed the superior mesenteric artery or celiac axis, and stage IV 
tumours which have widely disseminated are considered non resectable 
9
.   
 
 
Table 1.1 – TNM Staging of Pancreatic Cancer 9 where T denotes primary tumour, N 
regional lymph nodes, and M distant metastases 
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1.2.4 Treatment  
 
1.2.4.1 Surgery 
Around 15% of patients who present with pancreatic cancer are suitable for resection 
24
.  Two 
techniques are indicated for resecting cancer of the pancreas head.  Pancreaticoduodenectomy 
(known as Whipple procedure), entails removal of the pancreas head, gall bladder, 
duodenum, proximal jejunum, part of the extra hepatic biliary tree, and distal stomach.  The 
pylorus-preserving pancreaticoduodenectomy is identical to the classic Whipple procedure 
but with preservation of the pylorus.  A recent review evaluated the results of seven 
randomised controlled trials which compared these two operative techniques.  No differences 
were identified between them in terms of long-term survival, and mortality rates immediately 
following resection.  The rate of complications such as pancreatic anastomotic leaks and 
delayed gastric emptying were similar with both procedures 
11;25
.  Conversely, operating time 
and blood loss were reduced with the pylorus-preserving pancreaticoduodenectomy 
25
.  More 
radical surgery involving extended retroperitoneal lymph node dissection has not proved 
successful either in terms of overall survival or in preventing local recurrence of pancreatic 
cancer, and therefore is not regularly practiced 
26
.  Ghaneh et al 
27
 summarised the results of 
three randomised trials comparing radical and standard resection, and concluded that radical 
dissections do not improve survival. 
Prognosis following surgery can be predicted to some degree according to the presence of 
positive resection margins, tumour differentiation, the size of the tumour, and the 
involvement of lymph nodes 
11
.  Despite surgical intervention, 5-year survival remains as low 
as 10% with resection alone, and nearly all the patients who undergo a successful resection 
eventually relapse and die from the disease 
24;28
.  Adjuvant therapy in the form of 
chemotherapy and/or radiotherapy is provided in an attempt to improve survival and reduce 
disease recurrence 
14
.   
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1.2.4.2 Adjuvant therapy 
 
During the past few decades several well powered randomised controlled trials of adjuvant 
treatment following pancreatic cancer resection have taken place, and these have established 
the current standard of care.  One of the earliest investigations was the European Study Group 
for Pancreatic Cancer (ESPAC) 1 trial, which evaluated whether there was any benefit to 
adjuvant treatment following surgery to resect pancreatic cancer.  The findings demonstrated 
a survival benefit for chemotherapy, but not for chemoradiotherapy 
29
.   
 
The ESPAC 3 trial was later conducted to compare survival benefit of combined 5-
fluorouracil and folinic acid, versus gemcitabine alone.  No significant difference was found 
between these treatments in terms of progression-survival or quality of life scores, although 
gemcitabine was deemed safer 
29
.  On the contrary, another study reported a 1-year survival 
of 18% with gemcitabine, compared to only 2% with 5-fluorouracil 
14
.  Gemcitabine is now 
regarded as the optimal chemotherapy agent in the adjuvant and palliative treatment of 
pancreatic cancer.  The ESPAC 4 trial is currently recruiting patients and aims to compare 
gemcitabine against a combination of both capecitabine and gemcitabine 
24
. 
Other chemotherapy treatments have shown promise to act as adjuvant or palliative 
treatments.  For example, treatment with a combination of fluorouracil, folinic acid, 
irinotecan, and oxaliplatin led to a median survival of 11 months, compared to only 6.8 
months for gemcitabine alone.  However, adverse effects were significantly raised with the 
combination treatments, including higher incidences of grade 3 or 4 neutropoenia, 
thrombocytopoenia, and sensory neuropathy 
30
.  Such aggressive multichemotherapy 
regimens should therefore be reserved for younger patients who possess higher performance 
statuses and can tolerate stronger treatment 
8
.   
 
 
 
1.2.4.3 Neoadjuvant therapy 
 
 
Research findings support the use of adjuvant therapy whereas neoadjuvant therapy has yet to 
be proven worthwhile.  In fact, a recent meta-analysis found that whether or not neoadjuvant 
treatment is given, the proportion of patients who are eligible for resection is similar.  
11 
 
Furthermore, delaying surgical resection to provide neoadjuvant therapy could allow for 
disease progression, therefore after such therapy, patients should have their disease stage 
rechecked.  Neoadjuvant therapy is mainly reserved for borderline resectable disease where it 
has been shown to evoke a partial response, thus changing disease from borderline resectable 
to resectable 
11
.     
 
 
1.2.4.4 Investigational treatments for pancreatic cancer 
 
The ineffectiveness and toxicity of using multiple chemotherapeutic drugs has encouraged 
researchers to turn their attention to novel agents, including targeted therapies which have 
had success in other cancers.  The resilience of pancreatic cancer to chemotherapy may be 
due the multiple signalling pathways involved in its pathogenesis, thus suggesting that a 
single targeted agent is unlikely to be effective.  Alternatively, the surrounding desmoplasia 
may contain cells that promote tumour growth, as well as providing a physical barrier 
between the tumour and the rest of the body 
8
. 
 
Several targeted agents are undergoing clinical trials including PARP inhibitors, hedgehog 
inhibitors and multikinase inhibitors.  An important phase III trial recently investigated the 
benefit of an epidermal growth factor receptor (EGFR) inhibitor named Erlotinib in adjuvant 
therapy.  Unfortunately, when Erlotinib was combined with gemcitabine it was only modestly 
superior to gemcitabine treatment alone 
31
.  Immunological therapies such as an 
antitelomerase vaccine also hold considerable interest for further development 
32
.  The 
technique of using endoscopy to deliver chemotherapy or radiotherapy is now under 
investigation, though as yet no evidence exists that this method of delivery is as effective as 
standard methods 
33
.   
 
 
 
1.2.4.5 Palliative therapy 
 
A pancreatic tumour is inoperable if there is locally advanced disease, metastases, or the 
patient has a poor performance status 
9
.  Survival currently stands at approximately 9-10 
months for patients with locally advanced disease 
9
, but only 3-6 months in patients with 
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metastatic disease 
11
.  Pain is the most common symptom which requires control and is 
usually dealt with using oral opiate preparations.  However, if the pain originates from the 
coeliac plexus then infiltration with ablation of the plexus guided by ultrasound or CT can be 
performed.  Radiotherapy may also be used to relieve pain from locally advanced disease 
11
.  
Weight loss is common in advanced disease and can result from pancreatic insufficiency, 
common bile duct obstruction, or cachexia.  Cachexia cannot be treated, though obstruction 
of the common bile duct is an indication for biliary stenting 
9
.  Pancreatic insufficiency 
results from either pancreatic duct blockage or sparse pancreatic tissue, and can be treated 
with pancreatic enzyme supplements and/or stenting 
11
.    
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1.3 The Tumour Microenvironment in PDAC 
 
Surprisingly until very recently, the majority of research studies relating to pancreatic cancer 
have focused on the epithelial cell component of the tumour.  This is despite it being 
recognised for a long time that malignant tumours comprise a heterogeneous mixture of cells 
from different lineages including mesenchymal, endothelial, and inflammatory cells.  
Therefore, after years of rigorous research into the genomic instability of cancer cells, our 
attention has now shifted to consider the tumour microenvironment (TME) as well. 
In the context of PDAC, fibrosis stems from the accrual of surplus extracellular matrix 
proteins (ECM) in tissue, and is often referred to as tumour desmoplasia when associated 
with carcinoma 
34
.  The robust deposition of extracellular matrix during desmoplasia is 
directly related to the exuberant proliferation in mesenchymally and neuroectodermically 
derived cells 
35;36
.  Interestingly, the cell components in the TME are very similar to those 
that arise in response to tissue injury, hence various researchers have described the tumour as 
a wound that never heals 
36
. 
Histological analysis of tissue sections excised from patients with PDAC reveals infiltrating 
carcinoma cells surrounded by a dense stroma comprising type I and III collagens, fibronectin 
and laminin.  Collagen content is in fact 3-fold higher in the tissue of PDAC and CP 
compared to that of normal pancreas 
37
. 
Breast and prostate cancers also have prominent desmoplastic reactions.  In contrast to 
pancreatic cancer, research into epithelial-stromal interactions in these cancers was initiated 
several decades ago.  Early studies relating to the breast cancer microenvironment discovered 
the mitotic activity of stromal cells to be significantly increased in the vicinity of epithelial 
components, thus implying an interaction between the cell types 
38
.  
Furthermore, in breast cancer the presence of myofibroblasts is linked to a higher 
proliferative rate in tumour cells and a poorer prognosis 
39
.  The stromal influence on prostate 
carcinoma is also well documented.  Surprisingly, one report has shown the that the degree of 
reactive stroma can predict prognosis and disease recurrence even as accurately as the 
established serum marker, prostate specific antigen 
40
.     
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Research into the pancreatic cancer microenvironment may have progressed more slowly 
than that of breast and prostate not only due to less funding, but also perhaps due to 
difficulties encountered in accessing tumour tissue samples for analysis 
39
.  Amongst the 
tumours expressing desmoplasia discussed above, pancreatic cancer displays the most 
extensive desmoplastic reaction, with stromal tissue accounting for up to 90% of the tumour 
volume 
41
.  PDAC, the most common variety of pancreatic cancer, is very similar to breast 
cancer in histological appearance.  Tissue sections reveal a sparse duct-like structure with 
varying degrees of atypia surrounded by an intense desmoplastic reaction 
35
.  The identity of 
the different components of the TME, as well as their role in cancer initiation and progression 
is the focus of many current research efforts.  
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1.3.1 Which cells create the desmoplastic reaction?  
 
Pancreatic cancer cells have the capability to produce ECM components as proven in both in 
vitro and in vivo studies 
42
.  However, the majority of reports demonstrate that the mass of 
fibrotic tissue associated with PDAC and CP originates in the stroma rather than the tumour.   
Apte and colleagues 
43
 demonstrated that stromal areas of pancreatic cancer tissue sections 
stain intensely positive for collagen I, alpha SMA (Smooth Muscle Actin) and GFAP (Glial 
Fibrillary Acidic Protein), a molecular profile highly suggestive for activated pancreatic 
stellate cells (PSC).  Using in situ hybridisation they demonstrated that procollagen 
messenger RNA (mRNA) expression localised to activated PSCs, implicating these cells as 
the predominant source of collagen in PDAC.   
Data from Bachem and colleagues 
37
 reiterate these findings.  Immunohistochemical analyses 
showed alpha SMA positive cells to correlate with collagen type I and fibronectin.  Together, 
the ECM components and alpha SMA positive cells surrounded pan-cytokeratin positive 
carcinoma tissue.  There was clearly no association between the ECM proteins and pan-
cytokeratin staining.  Interestingly, they also discovered pan-cytokeratin staining to correlate 
with expression of extracellular matrix metalloproteinase inducer (EMMPRIN).  This implies 
that carcinoma cells have the ability to induce the formation of matrix metalloproteinases 
(MMPs) in neighbouring stromal cells. 
A similar study of pancreatic fibrosis has revealed that pancreatic acinar cells adjacent to 
areas of fibrosis exhibit intense staining for transforming growth factor beta (TGFβ).  This 
growth factor is a known activator and a profibrogenic mediator for PSCs.  Pancreatic acinar 
cells remote from any areas of fibrosis did not stain positively for TGFβ.  These results 
indicate the stimulation of PSCs by paracrine factors released from adjacent parenchymal 
cells 
44
. 
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1.3.2 The Pancreatic Stellate Cell 
 
Pancreatic stellate cells exist in a periacinar location in the exocrine portion of the healthy 
pancreas.  It is a cell type which comprises only 4% of the total number of cells in the organ 
45
.  In this location they exist in a quiescent state characterised by a star-like morphology and 
lipid droplets contained within their cytoplasm 
46
.  The lipid droplets contain vitamin A as 
evidenced by a rapidly fading blue-green fluorescence emitted on exposure to UV radiation 
47
.  The cells have a low rate of proliferation and a low capacity to produce ECM in this 
inactivated state. 
PSCs can be identified through immunohistochemistry staining techniques.  They express 
markers which are not specific to their own cell type, such as desmin and GFAP, both of 
which are cytoskeletal intermediate filament proteins also expressed by smooth muscle cells 
and astrocytes respectively 
47
.  Vimentin is a non-specific mesenchymal marker which has 
also been detected in PSCs. 
During pancreatic injury, PSCs enter an activated state which is accompanied by 
morphological and functional changes.  Cell morphology changes from a star shape to a 
‘myofibroblast-like’ phenotype, and lipid droplets disappear from the cytoplasm 37.  
Activated cells begin to express an additional marker, a cytoskeletal protein named alpha 
SMA.  They also develop the capacity to secrete large amounts of  ECM including collagens, 
fibronectin and laminin 
39
. 
A diverse number of extra-cellular and intra-cellular molecules induce this activation during 
pancreatic injury.  These include inflammatory cytokines such as IL-1 and IL-6, growth 
factors like TGFβ1 and TNFα, ethanol and its metabolites, and oxidative stress 37.  
Furthermore, Schneider et al 
48
 have demonstrated that platelet derived growth factor (PDGF) 
induces PSC proliferation, and TGF β1 induces the synthesis of ECM proteins by PSCs.  
Other important factors that PSCs have been shown to produce include MMPs, as well as the 
inhibitors of these enzymes named tissue inhibitors of metalloproteinases (TIMPs).  Hence, it 
is clear that PSCs play a major role in the maintenance of the surrounding stroma through 
both creation and degradation of the ECM 
35
.  
As mentioned above, the number of PSCs in the normal pancreas amounts to only 4% of the 
total cell number.  Conversely, in pancreatic cancer these cells can outnumber the malignant 
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epithelial cells, suggesting that they are recruited in large numbers and/or proliferate at a 
rapid rate 
35
. 
Stellate cells are capable of sustaining their activated state through autocrine signalling.  For 
instance, they generate growth factors such as TGFβ1, PDGF, connective tissue growth 
factor, as well as cytokines like IL1β, IL15, and endothelin 1 49.  
The persistent activated state of PSCs during CP and PDAC may also be partly explained by 
their ability to express the protease activated receptor-2 (PAR-2).  It is speculated by 
Masamune and colleagues 
50
 that as part of a positive feedback loop, PAR-2 stimulates PSC 
proliferation and collagen synthesis.  Interestingly, this protease only becomes active once it 
has been cleaved by trypsin, an enzyme which is highly abundant during pancreatic injury 
due to its leakage through the damaged exocrine ducts.   
    
 
1.3.2.1 ‘Quiescent’ state 
 
During health, PSCs exist in the quiescent state and are thought to play a central role in the 
normal maintenance of ECM turnover.  A recent study proposed that the PSC may even play 
role in normal exocrine function in the pancreas. Phillips et al 
51
 discovered that 
cholecystokinin (CCK) stimulates acetylcholine secretion by PSCs, which then induces 
acinar cells to secrete amylase.  Hence, these findings have shown a new pathway by which 
CCK is able to stimulate exocrine secretion in the pancreas.   
 
Quiescent PSCs also participate in temporary tissue repair processes following acute 
pancreatitis in both humans and rodents.  Their exact role in this scenario remains to be 
clarified although the likelihood is that they lay down a provisional matrix at the site of injury 
to allow for subsequent cell proliferation, migration, and the assembly of new parenchymal 
cells.  After the inflammation resolves the PSCs progressively disappear and may re-enter 
their quiescent state.  However, it is the repeated pancreatic damage that can lead to chronic 
inflammation and the persistent activation of PSCs 
52
.    
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The periacinar location of quiescent PSCs, together with their long cytoplasmic processes 
which encircle the basal aspect of the pancreatic acinar cells could signify a role in the 
maintenance of pancreatic acinar cells, or perhaps the regulation of ductal pressures 
47
.   
Additionally, their perivascular location suggests a possible role in the regulation of vascular 
functions 
45
.   
The function of the lipid deposits which rest in the cytoplasm of the quiescent PSC is yet to 
be clarified.  There is speculation that the vitamin A is required to maintain the quiescent 
state.  Hence, loss of vitamin A may be essential for the activation of the PSC rather than a 
mere epiphenomenon 
45
.  In support of this theory, retinol which is a vitamin A derivative, 
has been shown to inhibit the activation of stellate cells, and has even managed to induce 
quiescence in culture-activated stellate cells 
53
.  This induction was recently shown to be 
mediated by Wnt–β-Catenin Signaling 46.   
Clues to the function of PSCs can also be gleaned from research involving hepatic stellate 
cells (HSC) which have a very similar genotype.  HSCs have been assigned several important 
physiological roles in the liver, including vitamin A storage, creation and turnover of ECM 
proteins, promotion of hepatocyte differentiation, and the regulation of ductal and vascular 
pressures in the liver 
52
.  
 
 
1.3.2.2 Pancreatic cancer cells stimulate pancreatic stellate cells 
 
High numbers of activated PSCs have been observed to localise around pancreatic cancer 
cells in human tissue sections of PDAC 
43
.  This has led some to question whether the PSCs 
are attracted towards the cancer cells, and essentially recruited from the tissues surrounding 
the tumour by the cancer cells.  An alternative hypothesis is that cancer cells may be able to 
secrete growth factors or cytokines which increase stellate cell proliferation in the local 
vicinity of the tumour, leading to a greater number of stellate cells being detected around the 
cancer cells.   
Bachem and colleagues 
54
 have investigated whether such paracrine signalling exists through 
a series of in vitro experiments.  PSCs cultured in the supernatant of cancer cell lines had an 
19 
 
increased rate of proliferation, in comparison to those cultured in normal media.  In a 
subsequent experiment, a PDGF neutralising antibody was added to the cancer cell 
supernatant which resulted in a reduction in PSC mitogenic activity.  These results could 
indicate that PDGF controls proliferation of PSCs.  However, it is also possible that the 
PDGF neutralising antibody bound with other receptors on the PSC in addition, or apart from 
the PDGF receptor, thus indirectly inhibiting proliferation through other pathways.    
Wound healing assays and co-culture experiments have been performed by the same group.  
Cancer cell supernatant increased the rate of wound closure by PSCs, and during co-culture 
experiments, PSCs migrated towards the cancer cells.  Pre-incubation of PSCs with 
neutralising antibodies to PDGF reduced their motility in both experiments 
37
.  
Similar studies have been performed to investigate ECM production by PSCs.  When cultured 
in cancer cell supernatant, they stained more intensely for collagens and fibronectin, 
compared with PSCs cultured in normal media.  However, the addition of neutralising 
antibodies for TGFβ1 and basic fibroblast growth factor (FGF-2) to the cancer cell 
supernatant almost completely inhibited any matrix stimulating activity 
37
. 
A further finding is that cancer cells are able to induce MMP-2 synthesis in PSCs.  This 
through interactions with the PSCs via a glycoprotein called extracellular matrix 
metalloproteinase inducer (EMMPRIN), which is located on the cell surface of cancer cells.  
MMPs are another set of cells with critical roles in the development of pancreatic fibrosis, as 
well as the promotion of cancer cell invasiveness 
55
. 
The cell signalling pathways that regulate PSC activation have not yet been fully elucidated.  
It has been established that PDGF interacts with PSCs through Src-dependent activation of 
the JAK2-STAT3 pathway and the MAP kinase pathway, extracellular-regulated kinases 
(ERK)1/2 and p38.  Moreover, TGFβ1 has been shown to stimulate PSCs through SMADs 2, 
3 and 4 as well as the MAP kinases 
49
.  Therefore, a few of the molecular pathways that 
regulate the mitogenic and fibrogenic activity of PSCs have already been elucidated.  
However, our understanding of these processes, especially those controlling the activation of 
PSCs need to be improved, so that targets can be identified for therapeutic interventions that 
will aim to prevent or even reverse the activation of PSCs. 
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1.3.2.3 Pancreatic stellate cells promote tumour progression 
 
In an investigation by Vonlaufen and co-workers 
56
 conditioned medium of PSCs was shown 
to induce proliferation of pancreatic cancer cells at a significantly greater rate than that of 
cancer cells cultured in regular media.  Subsequently, a neutralising antibody to PDGF was 
added to the supernatant which then inhibited these mitogenic effects.  Migration and 
invasion were also induced in the cancer cells, as evidenced by Boyden chamber experiments 
and invasion assays respectively.  Interestingly, PSC supernatant was also shown to reduce 
cancer cell apoptosis as measured by TUNEL staining.  If the mechanisms by which PSCs 
inhibit cancer cell apoptosis could be elucidated, this could highlight favourable targets in the 
apoptotic pathway for which new pancreatic cancer therapies could be developed. 
The same researchers created an orthotopic mouse model of pancreatic cancer in order to 
investigate the interaction between cancer cells and stellate cells in vivo.  They found that 
mice injected with PSCs alone did not develop a pancreatic tumour.  However, mice injected 
with cancer cells developed tumours, and mice injected with both cancer cells and PSCs 
developed even bigger tumours.  Hence, PSCs alone do not have the potential to form a 
tumour, but instead play an important role in promoting the growth of cancer cells which are 
already present.   
Interestingly, none of the mice injected with cancer cells alone exhibited obvious fibrous 
tissue, although some of the cells within the stroma stained faintly for alpha SMA.  An 
explanation for this may be that the injected cancer cells recruited host murine PSCs at the 
tumour site.  On further investigation, tumour sections from the mice that were co-injected 
with PSCs and cancer cells were also studied to elucidate the origins of the activated PSCs in 
the tumour site.  They conducted immunohistochemical staining for alpha SMA and human 
nuclear antigen, the latter being a human cell-specific marker.  The results revealed that some 
of the alpha SMA positive cells within the tumour resulting from co-injection also did not 
express human nuclear antigen.  This implies that cancer cells managed to recruit and activate 
the PSCs belonging to the host species in order to enhance tumour growth.   
A role for PSCs in the promotion of cancer cell dissemination has also been proposed by the 
same investigation.  This is because a significantly higher proportion of the mice injected 
with a combination of PSCs and cancer cells developed distant metastases, compared to the 
21 
 
mice injected with cancer cells alone.  Furthermore, serial sections of liver metastases stained 
positively for both αSMA and human nuclear antigen 56.  This indicates that the tumour cells 
and PSCs are disseminating through the bloodstream together, which is contrary to previous 
belief that the cancer cells recruit new stellate cells at the distant site of dissemination.   
Hwang and colleagues 
57
 created a similar orthotopic mouse model of pancreatic cancer.  
They co-injected an immortalised PSC line with a cancer cell line.  Primary tumour 
incidence, size and metastasis were all increased with co-injection compared to cancer cells 
alone.  However, one must be cautious when interpreting these results due to the use of an 
immortalised PSC cell line instead of primary PSCs.  These immortalised cells were reported 
to have altered characteristics to primary cultured PSCs including a doubling time in culture 
of only 12 hours.  
In vitro studies by the same group reiterated the findings mentioned above, including the 
stimulation of tumour proliferation and invasion after culture of cancer cells in PSC 
supernatant.  Anchorage-independent growth as measured by tumour colony formation on 
soft-agar was also increased with PSC supernatant.  Furthermore, tumour cells treated with 
the conditioned medium of PSCs showed lower levels of apoptosis when subjected to both 
chemotherapy and radiotherapy 
57
.  However, these may have been indirect effects PSCs 
through their secretion of laminin and fibronectin, proteins which have previously been 
reported to have antiapoptotic effects 
56
. 
In a different study, Bachem et al 
54
 injected PSCs alone into the left flank of nude mice, and 
co-injected PSCs and cancer cells into their right flank.  All tumours that developed from co-
injection grew faster and progressed to a significantly larger tumour volume.  These results 
reiterate the findings from the vivo studies mentioned above, although the drawback of this 
investigation was that a xenograft mouse model was utilised rather than an orthotopic model.  
This does not allow for the assessment of tumour behaviour in its appropriate environment, as 
evidenced by the lack of metastatic pathways in that are available to a tumour in a 
subcutaneous model 
39
.    
Fujita and colleagues 
58
 investigated the behaviour of cancer cell lines when they were co-
cultured with PSCs.  Interestingly, they discovered that the behaviour of the cancer cells 
varied between direct and indirect co-culture systems.  Cancer cell proliferation was 
increased in direct culture with PSCs, compared to indirect co-culture.  Indeed, indirect co-
culture systems are generally more commonly used by researchers for in vitro studies, and 
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have eve been utilised for the co-culture experiments in most of the aforementioned studies.  
Direct co-culture also enhanced notch signalling pathways, whereas such induction was 
absent from indirect co-culture.  This implies that there must be direct cell to cell contact 
regulatory mechanisms that exist between cancer cells and PSCs, in addition to the paracrine 
mechanisms already discussed above. 
Xu and colleagues 
59
 have carried out a thorough investigation into the involvement of PSCs 
in tumour metastasis in pancreatic cancer.  They performed a gender mismatch study with 
male PSCs and female cancer cells in a female orthotopic mouse model.  Using fluorescent 
in-situ hybridisation they discovered that PSCs accompanied cancer cells during their journey 
from the primary tumour into the blood vessels and relocation to distant anatomical sites.  
These results support the findings made by Vonalufen et al 
56
 mentioned above, but are 
contrary to most previous beliefs that the cancer cells instead recruit new PSCs in the new 
metastatic site.      
As well as facilitating local growth and metastases, PSCs are also able to directly stimulate 
angiogenesis through their secretion of vascular endothelial growth factor (VEGF) and 
periostin 
41
.  These effects and their implications for tumour progression will be discussed in 
a later section. 
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1.3.2.4 Origin of pancreatic stellate cells 
 
It is widely agreed that PSCs play a fundamental role in pancreatic fibrosis, and many 
researchers are currently exploring the molecular mechanisms involved in the activation of 
these cells.  In contrast, the origin of these cells and their turnover within the pancreas is still 
debated.  It is commonly thought that most cancer associated PSCs arise from the existing 
pool of quiescent PSCs in the pancreas, although there is increasing evidence that there may 
be alternative sources 
39
.   
 
The involvement of bone–marrow (BM) derived cells in organ fibrosis has been portrayed in 
a number of studies.  A study conducted by Russo and colleagues 
60
 found that a large 
proportion of the myofibroblasts (70%) and hepatic stellate cells (68%) present during liver 
fibrosis had originated from the BM.  The same process may occur in the pancreas during 
fibrosis although there is currently limited data to support this.  However, the fact that PSCs 
and HSCs are 99.9% similar at the mRNA level suggests that they may even possess a 
common origin.    
In a recent pancreatic study, Sparmann et al 
61
 compared the origins of isolated quiescent 
PSCs in normal rat pancreas, with those isolated from restored rat pancreas following an 
artificially induced episode of acute pancreatitis.  The incidence of BM derived quiescent 
PSCs obtained from rat pancreas was approximately 7% from healthy pancreatic tissue, and 
18% from the restored pancreas, a significant difference.  The increased numbers of quiescent 
PSCs present in the pancreas after regeneration propose the enhanced recruitment of BM-
derived cells to the pancreas, which have subsequently reverted back to their quiescent state 
after the resolution of the inflammatory process.   To the author’s best knowledge this is the 
first publication to reveal a BM origin for quiescent PSCs.         
Mesenchymal stem cells (MSC), which originate from the bone marrow have been shown to 
localise to areas of pancreatic tumour growth 
62
.  More importantly, Direkze and colleagues 
63
 
have shown that BM-derived cells MSCs also contribute to the myofibroblast population in a 
mouse model of insulinoma.  Further investigations are needed to elucidate whether this is 
also the case in PDAC. 
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Contribution of endothelial cells to the myofibroblast cell population in pancreatic cancer has 
been reported by Zeisberg et al 
64
.  This phenomenon of endothelial to mesenchymal 
transition occurred through induction by TGFβ1 treatment, causing proliferating endothelial 
cells to convert phenotypically into fibroblast-like cells, with subsequent expression of 
mesenchymal markers. 
The relative contributions of resident precursor cells, as well as BM-derived cells and MSCs, 
to the activated stellate cell population in the diseased pancreas requires clarification 
52
.    
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1.3.3 The extracellular matrix 
 
The extracellular matrix (ECM) in healthy organs provides cells with a tensile scaffold 
necessary for appropriate assembly into three-dimensional macroscopic structures 
65
.  It is 
composed of collagens, non collagen glycoproteins, proteoglycans, and growth factors.  
There are also matricellular proteins within the matrix which lack a structural role, but 
instead act as modulators for the interactions between the cell components and the 
surrounding matrix 
49
.  These include connective-tissue growth factor (CTGF), secreted 
protein acidic and rich in cysteine (SPARC), thrombospondin and periostin. 
 
 
1.3.3.1 Role of the ECM in tumour progression 
 
The excess fibrous tissue found in and around the diseased pancreas was initially believed to 
be a host barrier against cancer invasion.  In keeping with this belief, the development of a 
tumour suggested that cells had overcome the architectural constraints imposed by the matrix 
in order to multiply and survive, even in the absence of permissive interactions with the ECM 
65
. 
Current evidence suggests that the matrix can modulate carcinogenesis by providing a 
supporting structure for tumour growth, as well as by acting as a reservoir for the storage of 
soluble signalling molecules.  These can enhance cellular growth, differentiation, survival, 
and movement of the cancer cells 
20
.  
Type I collagen, one of the most abundant collagens present in the ECM of pancreatic cancer, 
is secreted predominantly by PSCs.  The collagen itself has been shown to increase the 
proliferation, migration and resistance to apoptosis of pancreatic cancer cells, mediated via 
signalling via its integrin receptors 
66
.      
Armstrong et al 
67
 used tissue culture models to demonstrate that ECM proteins are able to 
enhance tumour growth.  Cancer cell lines cultured on type I collagen showed higher rates of 
proliferation compared to those cultured on plastic.  The degree of apoptosis was significantly 
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reduced in the cells cultured on type I collagen when all the cells were administered 
chemotherapy in vitro.  These results were corroborated in multiple pancreatic cancer cell 
lines.  Similar results were elicited in a small-cell lung cancer in vivo model which displayed 
how ECM proteins are able to protect cancer cells from apoptosis again mediated by integrin 
receptor signalling 
68
.  On the other hand, the results of these investigations may be seen as 
unconvincing if one assumes that cancer cells simply prefer to grow on a three-dimensional 
tissue matrix system which is more akin to their original environment, rather than the two-
dimensional growth provided by a plastic coasted dish.  This would explain the enhanced 
growth of cancer cells on the collagen surface. 
As well as modulating carcinogenesis, the fibrotic matrix also serves as a protective barrier 
against potential therapeutic strategies such as chemotherapy and radiotherapy.  The 
excessive matrix creates a hypoxic and hypovascular environment, making it difficult to 
access the tumour via the bloodstream.  Olive et al 
69
 characterised tumour perfusion in a 
mouse model of pancreatic cancer, and evaluated intratumoural uptake of gemcitabine 
therapy.  Their data highlighted inefficient tumoural uptake of gemcitabine as a direct result 
of poor vascularisation and perfusion within the tumour. 
Growth factors like epidermal growth factor (EGF), fibroblast growth factor (FGF), PDGF 
and TGFβ exist within the matrix.  These may be released through protease mediated 
digestion of the ECM which allows them to carry out their roles, one of which includes the 
activation of PSCs.  Farrow and colleagues 
70
 have detected high expression of EGF specific 
to the stromal compartment, and high expression of EGFR specific to cancer cells.  This 
implies that cancer cells are stimulated by their neighbouring stromal cells through EGF. 
The expression of ‘anti-adhesive’ ECM proteins within the stroma can facilitate pancreatic 
cancer cell invasion.  Such proteins include tenascin, vitronectin and versican.  Versican is 
secreted by cancer cells as well as by activated stellate cells 
70
.   
High levels of the SPARC expression originate from the stroma of the pancreatic tumour, and 
it has also been detected in the conditioned medium of PSCs 
71
.  The expression of this 
matricellular protein has been linked with a poor prognosis, and experimental studies have 
demonstrated the ability of this protein to increase pancreatic cancer cell invasiveness 
49
.  In 
contrast, other reports concluded that SPARC possesses tumour suppressing functions.  For 
example, inhibition of endogenous SPARC in cultured cancer cells enhanced their 
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proliferation and migration 
71
.  Clearly further studies are required to elucidate the role of 
SPARC in pancreatic cancer. 
Periostin is another matricellular protein that has been detected in the supernatant of PSCs.  
This expression is up-regulated in PSCs when they are co-cultured with pancreatic cancer 
cells.  This protein seems to have a biphasic effect on cancer cell motility, where low 
concentrations suppress motility whereas high concentrations increase it 
72
.  Perhaps, the 
effects of SPARC are also dose-dependent like those of periostin.  Finally, the role of 
thrombospondin has also been described.  It has been associated with increased pancreatic 
cancer cell invasion, and its presence within the stroma is correlated with a poor prognosis. 
   
1.3.3.2 Role of the ECM in tumour initiation 
 
The studies mentioned above depict evidence for why the ECM is able to promote tumour 
progression in the pancreas.  However, the role of the ECM in the oncogenic conversion of 
normal epithelial cells has also been suggested.  The reduced physical compliance of the 
ECM, due to excessive deposition of collagen in tumours is apparently enough to initiate 
carcinogenesis.  Changes in matrix rigidity are detected by surface receptors called integrins 
which connect to the cytoskeleton and translate this external information to the cell.  Cell 
contractility is subsequently modified through the activity of Rho GTPases, a family of 
proteins involved in the regulation of a variety of cellular processes, such as the organization 
of the microfilamental network and cell-cell contact 
65;73
.   
Paszek et al 
74
 cultured normal mammary epithelial cells on rigid substrates, which 
subsequently caused altered cell phenotypes with traits of neoplastic transformation.  Such 
changes included disruption of cell to cell contacts, depolarisation, increased production of 
focal adhesions, and most importantly an increased receptiveness to proliferative signals from 
EGF stimulation.  Interestingly, these changes could be repeated when Rho was artificially 
stimulated in normal mammary epithelial cells which were cultured in the absence of a stiff 
matrix.  Furthermore, the authors discovered that mammary carcinoma cells spontaneously 
overexpress Rho, and inhibition of Rho or its downstream effectors could even reverse the 
phenotypic changes described above 
65
.    
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1.3.3.3 Interaction of the ECM with Pancreatic Stellate Cells 
 
The ECM is believed to regulate PSC behaviour for several reasons.  Firstly, experimental 
data has shown PSCs to revert to their quiescent state if cultured on a basal membrane-like 
matrix.  Furthermore, in hepatic fibrosis, extensive degradation of the ECM has resulted in 
the apoptosis of HSCs presumed to be as a result of reduced survival signals being received 
from the ECM 
75
.  More recently, a mouse model was created which lacked plasminogen in 
order to represent impaired proteolysis of the ECM and a constant fibrotic matrix.  This led to 
persistent PSC activation and accumulation of pancreatic collagens 
52
.  This implies that 
certain components in the ECM are promoting the proliferation or survival of PSCs.  
Proteoglycans such as decorin, lumican, and versican are present in large quantities within 
the ECM in pancreatic cancer, and PSCs are thought to be the main source of these proteins.  
Versican stimulates cancer cell invasiveness and dissemination, whereas decorin and lumican 
seem to have tumour suppressing effects.  Interestingly, PSCs cultured in the supernatant of 
pancreatic cancer cells increased their secretion of versican, but downregulated their 
expression of decorin and lumican.  These results highlight the ability of cancer cells to 
manipulate their environment to make it less hostile and aid survival 
49
. 
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1.3.4 Matrix metalloproteinases 
 
1.3.4.1 Role of MMPs and other proteases in tumour progression 
 
Matrix metalloproteinases (MMP) are a large family of zinc-containing proteolytic enzymes 
directly involved in ECM remodelling 
41
.  One of the most important functions of MMPs is 
their ability to degrade type IV collagen, a component of the basement membrane.  Digestion 
of this membrane allows cancer cells to invade local lymphatic channels and blood vessels, 
thus representing a critical step in tumour progression 
35
.  Invasion of the surrounding 
environment also brings malignant cells into contact with other ECM proteins such as 
collagen type 1, which can directly support cancer cell growth and contribute to their 
chemoresistance as mentioned in section 1.3.3.1 
20
.   
MMPs also regulate the bioavailability of growth factors and cytokines contained within the 
ECM.  These molecules are released when MMPs digest the ECM, and their release 
subsequently has effects on tumour proliferation, angiogenesis and metastasis.  Moreover, the 
transcriptional regulation of MMPs is regulated by these cytokines and growth factors 
contained within the ECM.  For example, TGFβ1 has been shown to up-regulate collagens, 
MMP-2 and TIMP-1, whilst down-regulating TIMP-2, MMP-3, and interstitial collagenases 
such as MMP-1 and -13 secretion by fibroblasts 
76
.   
The presence of MMP-1, -2, -3, -7, -9, -11, and -13 have all been reported in PDAC.  MMP-2 
and -9 are both highly expressed in cancer cells, but are also secreted by PSCs and 
macrophages 
36
.  As well as digestion of basement membrane collagen (Type IV), they also 
have the ability to digest the partially degraded collagens (Types I, III) 
77
.    
Other than degradation of ECM components and release of sequestered growth factors, 
MMPs also promote tumour progression through complex signalling functions.  For example, 
in vitro studies have shown that angiostatin, a potent angiogenesis blocker is cleaved from 
plasminogen by MMP-2, -3, -7, -9, and -12.  Also, insulin like growth factor binding proteins 
and stromal cell derived factor are both cleaved and inactivated through MMP activity.  
Therefore, we must decipher which proteases are contributing to tumour progression, and 
30 
 
which are acting as part of the host defence.  This is a necessary step in determining which 
MMPs are potential drug targets 
78
. 
Research into squamous cell carcinogenesis has revealed that MMP-9 manifests 
proangiogenic activity in its ability to mobilise VEGF from the ECM 
79
.  On the contrary, 
MMP-9 is can cleave collagen IV to produce a proteolytic fragment named tumstatin, which 
possesses anti angiogenic properties 
36
.  The mixture of pro- and anti-tumourigenic roles of 
MMPs may account for the failure of MMP inhibitors in recent clinical trials.  For instance, 
when combined with gemcitabine they displayed no superiority in outcome compared to the 
standard gemcitabine treatment alone 
14;78
.  TIMPs are also often overexpressed in tumours 
along with their target proteinases.  This suggests that TIMPs probably have several roles in 
tumour promotion, rather than inhibition of MMPs alone 
41
. 
MMP-7 also known as Matrilysin is expressed in PDAC, predominantly by epithelial cells in 
the invasive tumour front.  Its expression in PDAC has been associated with an advanced 
pathological stage and poorer survival.  Futhermore, MMP-11 (stromelysin-3) is also 
expressed in PDAC typically by stromal cells which are located adjacent to the tumour 
36
.   
Apart from MMPs, various other proteases and their inhibitors exist within the TME.  In a 
recent study researchers induced a cancer cell line to overexpress the protease inhibitor 
SERPINE2.  They then compared local invasiveness between the tumours resulting from 
induced or non induced cells injected into the xenograft model.  Pancreatic tumours 
developing from the induced cancer cells displayed greater local invasiveness which was 
accompanied by a striking increase in ECM deposition.  Furthermore, they discovered that 
tumour growth was also increased in addition to local invasion, if the SERPINE2 
overexpressing cells were co-injected with PSCs 
80
. 
Urokinase plasminogen activator (uPA) and tissue plasminogen activator (tPA) are 
proteolytic enzymes regulated by the pancreatic cancer stroma, and their increased expression 
has been associated with an increase in pancreatic cancer cell invasion 
70
.  
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1.3.4.2 The role of MMPs in cancer initiation 
 
A recent breast cancer publication has suggested that MMPs are able to initiate 
carcinogenesis 
81
.  A transgenic mouse model characterised by overexpression of MMP-3 
expression demonstrated the appearance of premalignant lesions, followed by the 
development of overt mammary carcinomas.  They managed to clarify the sequence of 
molecular events taking place.  Firstly, EMT was induced by MMP-3 through the 
upregulation of Rac1b, a small GTPase with a role in the maintenance of the actin 
cytoskeleton.  This upregulation led to the production of reactive oxygen species (ROS), 
specifically mitochondrial superoxide.  Elevated levels of superoxide anions induced Snail 
expression, a transcriptional repressor of E-cadherin which is an epithelial cell to cell 
adhesion molecule.  This explained the transformation from an epithelial to a mesenchymal 
phenotype 
65
.   
It is fascinating that an enzyme previously believed to have a solitary role in digesting ECM 
has now been shown to cause genomic instability in normal cells.  MMP-3 may be directly 
responsible for the acquisition of mutations in these epithelial cells, or alternatively it may 
provide a stromal environment which supports the survival of cellular clones bearing selected 
mutations 
65
. 
 
1.3.4.3 Interaction of MMPs with pancreatic stellate cells 
 
Pancreatic stellate cells are able to secrete both MMPs and TIMPs and therefore play a 
central regulatory role in pancreatic fibrosis by controlling matrix turnover.   
EMMPRIN is frequently raised in various solid tumours including breast and ovarian cancer, 
in which its overexpression is correlated with tumour size, stage and prognosis 
41
.  It is also 
expressed on the cell surface and in the supernatant of several pancreatic cancer cell lines.  
PSCs cultured in the supernatant of the cancer cells have increased expression of MMP-1 and 
-2.  However, if PSCs were cultured in supernatants depleted of EMMPRIN, this led to an 
inhibition of MMP expression 
55
.  These data imply that the cancer cells are stimulating 
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adjacent PSC secretion of MMPs in a paracrine fashion, as opposed to through cell to cell 
contacts. 
In a different report, TGFβ1 has been demonstrated to reduce the expression of MMP-3 and -
9 by PSCs.  As mentioned in section 1.3.2.3, TGFβ1 is also expressed by PSCs themselves.  
Hence, PSCs may enhance fibrogenesis by inhibiting ECM degradation via autocrine 
signalling which inhibits their own production of MMP -3 and -9 
77
. 
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1.3.5 Fibroblasts  
 
Fibroblasts are derived from the primitive mesenchyme embryonic layer and stain positively 
for vimentin, an intermediate filament protein.  In the healthy pancreas, fibroblasts form a 
fundamental part of residential connective tissue support.  They are usually modest in 
number, but show proliferation in different forms of pancreatic injury including pancreatitis 
and pancreatic cancer 
36
. 
The functions of quiescent PSCs are proposed to be analogous to those of fibroblasts in the 
healthy pancreas and have previously been discussed in section 1.3.2.1.  Additional 
similarities between these cell types include their periacinar and periductal location, and the 
rapid production of ECM components upon activation, including type I, III, and V collagens 
and fibronectin 
82
.  Despite these similarities in function, it is now well accepted that PSCs 
are the main contributors of the excessive fibrotic tissue in the pancreas during disease states 
as explained in Section 1.3.1 
35
.  
Fibroblasts are elongated cells with extended cell processes that show a fusiform or spindle-
like shape in profile.  As well as vimentin, molecular markers include fibroblast specific 
protein 1 and CD90.  However, the lack of a specific and reliable molecular fibroblast marker 
acts as a hindrance to studying these molecules in vivo.  Myofibroblasts represent activated 
fibroblasts that are able to produce greater amounts of ECM, and can be distinguished from 
the normal fibroblast by their expression of alpha SMA 
83
.  
Fibroblasts in mammals are highly heterogeneous, and a recent study has identified divergent 
gene-expression patterns between fibroblasts isolated from different anatomical sites within 
the same patient.  Surprisingly, these disparities in gene expression were even as divergent as 
the variation between the lineages of white blood cells in the same patient 
82
.  
The signals that mediate the transition of a normal fibroblast into a cancer associated 
fibroblast (CAF) are not yet fully understood.  However, in vitro studies have shown that 
TGFβ can induce phenotypic features of CAFs in normal fibroblasts.  This growth factor 
mediates these changes during fibrosis and wound healing.  Further studies are needed to 
elucidate whether CAFs represent a unique subtype of the fibroblast, or merely a common 
phenotype of fibroblast activation during injury 
82
. 
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Several studies have demonstrated the role of fibroblasts in cancer initiation.  For example, 
Kuperwasser and colleagues 
84
 demonstrated that over-expression of TGFβ by fibroblasts in 
their transgenic mouse model resulted in the initiation of breast cancer within the adjacent 
epithelial tissue.  Similarly, another study compared primary fibroblasts isolated from normal 
tissue, to CAFs isolated from tumour tissue.  Normal prostate epithelial cells were grafted 
into mice along with one of these fibroblast types.  However, only the epithelial cells grafted 
alongside CAFs induced tumourigenesis 
82
.   
Mesenchymal stem cells (MSC) are fibroblast-like progenitor cells.  Their phenotypic 
markers include LNGFR and STRO-1, however no specific marker for the MSC has been 
discovered.  They originate from the bone marrow and have the capacity for self renewal and 
to differentiate into several other cell types including osteocytes, chondrocytes and 
adipocytes.  Their differentiation into PSCs has also been debated (Section 1.3.2.4).  It is 
likely that they represent a subtype of fibroblasts due to similarities including a spindle 
shaped morphology and expression of the CD90 marker 
85
. 
There are currently few if any studies which have discussed the role of MSCs in pancreatic 
cancer intiation and progression.  However, Karnoub et al 
86
 investigated the effects of MSCs 
in tumour progression in a breast cancer xenograft mouse model.  They injected a mixture of 
human bone-marrow MSCs and human breast cancer cells into several mice, and breast 
cancer cells alone into different mice.  After 12 weeks the mice developed malignant 
tumours.  However, distant metastases were only observed in mice injected with MSCs.  
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1.3.6 Immune cells  
 
1.3.6.1 Lymphocytes 
 
Dendritic cells regulate the production of functionally competent T cells.  These cells are 
situated in tissues throughout the body and their designated role is to absorb antigens from 
their surrounding environment.  Once loaded with antigens they migrate to the nearest 
lymphoid organ to present them to naive T cells.  The T cells then become activated, which 
subsequently enables them to identify cancer cells that display cancer-specific antigens on 
their cell surface. 
The Bone marrow (BM) is already known for its role as a primary lymphoid organ due to its 
ability to generate lymphocytes from immature progenitor cells.  However, a recent study has 
shown that the BM is able to serve as a secondary lymphoid organ as well.  The authors 
demonstrated that naive, antigen specific T cells in the blood home to the BM for priming.  
Additionally, they showed that CD11c
+ 
dendritic cells take up exogenous antigens from the 
blood and present them to resident T cells in the bone marrow.  Hence, these two methods 
represent ways in which antigen specific T cells are able to undergo activation, proliferation 
and differentiation to form effector T cells that enter the bloodstream as a result of exposure 
to cancer antigens 
87
.     
Another recent study has supported this notion.  The BM was discovered to be imperative in 
producing CD4
+ 
and CD8
+ 
T cells that are specific to various antigens in PDAC.  Primed 
memory T cells specific to cancer antigens were detected in all 41 of their patients with 
PDAC.  Around a half of these memory T cells were also identified in the bloodstream of 
these patients 
88
.  Conversely, similar studies of melanoma and multiple myeloma patients 
identified primed memory T cells in the bone marrow of less than half of their patients 
20
.  
However, the higher proportion of T cell responses discovered in PDAC could be attributed 
to its late clinical presentation meaning that greater quantities of cancer antigens are able to 
reach the BM by the time of diagnosis and BM sampling. 
The type and extent of T cell response differs according to the antigens that are presented.  
For example, ECM breakdown products and type I interferons may encourage activation of T 
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cells in cancer tissues, whereas TGFβ and IL-10 have immunosuppressive effects.  The latter 
are both produced in large quantities in PDAC by various cells in the TME including PSCs 
89
, 
macrophages, mast cells 
90
 and regulatory T cells 
91
.   
In support of these findings, Von Bernstorff et al 
91
 analysed 116 patients suffering with 
PDAC and discovered mean concentrations of TGFβ and IL-10 to be significantly higher in 
the sera of PDAC patients to those of patient controls.  Moreover, loss of CD3 in the T cells 
of patients with PDAC was elicited with immunohistochemical staining.  CD3 is a membrane 
complex essential for signal transduction and subsequent activation of T cells.  Its loss was 
also correlated with elevated concentrations of TGFβ and IL-10.   
Freshly isolated CD8
+ 
T cells are able to recognise and lyse autologous pancreatic cancer 
cells in vitro.  These primed CD8
+ 
T cells were also injected into a xenograft mouse model of 
PDAC which significantly delayed tumour progression 
92
.  These results are supported by the 
findings of Fukunaga et al 
93
 who reported a correlation between higher numbers of cancer-
infiltrating CD4
+ 
and CD8
+
 T cells and a better prognosis in PDAC. 
As a result of the dense desmoplastic stroma surrounding pancreatic tumours, activated T 
cells may have difficulty accessing the cancer cells.  In fact, a recent study found that tumour 
infiltrating lymphocytes became trapped in peritumoural tissues and were not able to reach 
the cancer cells in significant numbers 
91
.  This was seen in 28 of 33 dissected surgical 
specimens from patients with PDAC.  
Cancer cells adapt in several other ways which help them remain undetected and to avoid 
being destruction by T lymphoctyes.  For example, major histocompatibility complex (MHC) 
proteins and the fas receptor are both down-regulated in cancer cells, thus rendering them 
more resistant to the action of infiltrating T cells.  The fas ligand is capable of inducing 
apoptosis in cells, and cancer cells also overexpress this.  Furthermore, neoplastic cells have 
been shown to recruit and maintain local regulatory T cells, which act to inhibit both T cell 
activation and function 
20
. 
Here one can conclude that pancreatic cancer is characterised by an abundance of cell 
mediated immunity.  However, several mechanisms are in place to create a potent barrier and 
help protect the tumour from the action of activated T cells in situ.  These alterations in the 
TME have been termed ‘tolerising’conditions.  This represents the fact that neoplastic cells 
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are able to mimic signalling pathways of the immune system in order to propagate conditions 
that favour immune tolerance 
94
. 
 
1.3.6.2 Inflammatory cells 
 
Immunohistochemical analysis of PDAC sections by Aoyagi et al 
95
 revealed that a large 
number of neutrophils were located at the invasive front of the tumour.  These cells expressed 
high levels of TGFβ which in turn correlated with large amounts of collagen production.  
Emmrich and colleagues 
96
 also used immunohistochemistry to demonstrate increased 
numbers of macrophages in the stroma in PDAC and CP, compared to that of healthy 
pancreatic tissue.  Macrophages were the predominant subtype of immune cell in normal 
tissue, although in both PDAC and CP the predominant subtype was infiltrating T 
lymphoctyes.   
Macrophages are derived from monocytes in the circulation which are drawn to tissues 
through the secretion of MCP-1, levels of which are raised both in PDAC and CP.  The 
presence of the ECM component decorin is closely related to the expression of  the MCP-1 
protein 
70
.  Therefore, through mechanisms yet to be clarified, decorin may be responsible for 
drawing macrophages to the TME.  Such an idea supports previous findings of the tumour 
suppressive functions of decorin.  It also highlights that PSCs could indirectly affect immune 
processes through their ability to secrete decorin during pancreatic disease (See Section 
1.3.3.3).  
The presence of inflammatory cells within the stroma of PDAC has been correlated with 
increased angiogenesis, a recognised indicator of a poor prognosis 
90
.  Macrophages secrete 
proangiogenic growth factors such as VEGF, thus increasing both angiogenesis and 
metastatic potential.  Macrophages are also able to secrete several interleukins which 
stimulate tumour local growth and invasion.  For example, IL-1 decreases the adhesion 
between cancer cells and their surrounding basement membrane proteins including Laminin, 
thus promoting motility and cancer spread 
35
.  Moreover, IL-6 is released which activates 
PSCs, thus promoting tumour growth through greater ECM deposition as well as other effects 
previously discussed in Section 1.3.2.3.  Finally, IL-8 secreted by macrophages has been 
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shown to increase the growth rate and likelihood of metastasis in an in vivo model of 
pancreatic cancer 
70
.   
Cyclooxygenase-2 (COX-2), an enzyme that mediates inflammation in non-cancerous cells, 
has now been proposed as an important promoter of cancer cell invasion.  Co-culture studies 
of pancreatic cancer cells with cancer associated fibroblasts have demonstrated upregulation 
of the COX-2 gene in both parties.  Also, in vitro invasion assays revealed an increased 
invasive potential for the cancer cells during co-culture, an effect which was partially 
inhibited when a COX-2 inhibitor was added to the media 
97
.  This inflammatory enzyme can 
also affect PSCs, specifically their proliferative rate.  Activated PSCs are capable of secreting 
COX-2, although when cultured in cancer cell supernatant this expression was significantly 
increased.  The addition of an inhibitor of COX-2 to the media decreased proliferative rate, as 
well as reducing the PSC’s own secretion of COX-2 98.   
 
 
1.3.6.3 The immune system and cancer initiation 
 
Few T or B lymphocytes are detected in the scant stroma of the healthy pancreas.  The 
situation in CP varies with substantial lymphocytic infiltration of the stroma and often K-ras 
mutation.  Animal studies have demonstrated that K-ras mutation by itself cannot lead to 
PanINs or PDAC.  However, animals induced with both CP and K-ras mutation are able 
develop PDAC 
35
.   
A review by Farrow et al 
99
 explores how pancreatic inflammation, mediated by cytokines, 
reactive oxygen species, and upregulated pro-inflammatory pathways plays a key role in the 
early development of pancreatic malignancy.  This is through increased cell cycling, 
disruption of cell differentiation, and the loss of tumour suppression with increased 
stimulation of oncogenic expression.  According to van Heek and colleagues 
100
 increased 
intracellular ROS formation may lead to DNA damage and contribute to telomere shortening, 
changes which are widely observed in PanINs. 
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1.3.7 Vascular cells and angiogenesis 
 
The main vascular cells which make up the TME include endothelial cells, pericytes, and 
vascular smooth muscle cells.   
Pericytes are embedded within the basement membrane of blood microvessels adjacent to 
endothelial cells, both of which are important regulators of vascular development and 
remodelling 
101
.  They exist as precursor cells which demonstrate functional plasticity in their 
ability to differentiate further into vascular smooth muscle cells or collagen secreting stromal 
cells 
36
.       
Endothelial cells are fully differentiated cells which are stimulated by the family of growth 
factors named VEGF.  Their level of activity is determined by the dynamic balance between 
proangiogenic factors and endogenous angiogenic inhibitors 
36
. 
VEGF promotes angiogenesis during embryonic development and is imperative to wound 
healing in healthy adults.  During tumourigenesis, it is upregulated by oncogene expression, 
growth factors, inflammation and hypoxia to promote angiogenesis.  Before a tumour can 
grow beyond 1-2 mm, it requires blood vessels for nutrients and oxygen.  The release of 
VEGF and other growth factors prompts the formation of new blood vessels which allows the 
exponential growth of the tumour 
4;102
.   
The blood vessels that form by VEGF secretion in tumours are irregular in terms of structure 
and function.  They are leaky and haemorrhagic, and lack the organisation into venules, 
arterioles, and capillaries like in normal vasculature.  The resulting blood flow is suboptimal, 
resulting in hypoxic conditions and further VEGF secretion 
102
. 
Our knowledge relating to angiogenesis in PDAC is less advanced compared to that of 
pancreatic islet cell carcinogenesis.  Using their mouse model of islet cell carcinogenesis, 
Hanahan et al. 
103
 proposed a multi-stage process in which angiogenesis is initiated in 
dysplastic tissues before the formation of any tumour.  This has been termed the ‘angiogenic 
switch’.  VEGF-A plays a key role in this progression, in addition to PDGF mediated 
signalling from endothelial cells to pericytes.   The ’angiogenic switch’ is considered off 
when there is a balance between the effects of pro-angiogenic and anti-angiogenic molecules.   
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Pancreatic cancer tissues are hypoxic and have a low microvessel density unlike those found 
in islet cell tumours, and most other solid malignancies.  However, this cancer, like all other 
cancers still depends on an angiogenic process 
20
.  Over-expression of VEGF and its 
receptors has been associated with a poor prognosis and increased metastatic potential in 
pancreatic cancer 
41
.  It has been demonstrated that the VEGF/VEGF-RII pathway regulates 
angiogenesis in PDAC.  Genetic down-regulation of VEGF-RII has been shown to inhibit 
both local growth and the likelihood of metastases 
104
. 
Abdollahi and colleagues 
105
 carried out transcriptional profiling to identify proangiogenic 
factors in a large number of human pancreatic tissue samples.  They compared normal 
pancreatic tissue, chronic pancreatitis, and primary and metastatic PDAC.  They reported a 
gradual increase in the levels of proangiogenic factors, and a gradual decrease in anti-
angiogenic factors as samples progressed from normal, to inflamed and to cancerous tissue.  
These authors also believe that there is an ‘angiogenic switch’ that arises after PDAC could 
have been lying in a microscopic, dormant state for months or years.  They propose that after 
prompting this switch, the dormant cancer becomes rapidly proliferative and develops the 
potential to disseminate 
20
.   
The growth factors which stimulate the ‘angiogenic switch’ can emanate from cancer cells, 
PSCs, fibroblasts, the ECM, in addition to endothelial cells themselves 
106
.  Furthermore, 
TME components including mast cells, monocytes and tumour cells have demonstrated 
secretion of VEGF-A, VEGF-C and bFGF in culture 
36
.   
Angiogenic receptors are not only expressed on vascular cells, but also on cancer cells.  For 
example, VEGF-RI is found in PDAC cell lines, and once activated encourages their 
migration and invasion.  Therefore, theoretically, anti-angiogenic therapies will not only 
inhibit angiogenesis, but will also stop the autocrine stimulation of pancreatic cancer cells 
20
. 
Promising results have been elicited in vivo when VEGF receptor blockers combined with 
gemcitabine therapy reduced tumour volume in metastatic pancreatic cancer 
107
.  However, 
other studies have demonstrated that targeting VEGF with inhibitory agents causes the 
tumour to adapt and begin to produce a wider array of angiogenic molecules.  For example, if 
VEGF is blocked then tumours can secrete other angiogenic molecules instead, such as IL-8 
or bFGF.  Moreover, COX-2 and NRP-1 are additional angiogenic factors, whose expression 
is linked to a poor prognosis in pancreatic cancer.   
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1.4 MicroRNA 
 
 
MicroRNAs (miRNA) are a class of small (~22 nt) non-coding RNA molecules with gene-
regulating functions, discovered under two decades ago.  They have been implicated in a 
whole host of cellular processes including the epigenetic regulation of cancer related genes 
108
.  This has earned them a great deal of attention from the scientific community.  Their 
importance has been further emphasised by recent evidence that each miRNA may control 
hundreds of gene targets.  Therefore, it is staggering to consider the number of already 
recognised genetic pathways that miRNAs could affect 
109
.  
 
 
 
1.4.1 Biogenesis, functions and targets 
 
The first step of miRNA maturation takes place in the nucleus where the long primary 
transcript (pri-miRNA) is cleaved into a shorter stem-loop intermediate around 60-70 
nucleotides in length, known as a precursor miRNA molecule (pre-miRNA) 
110
.  This 
processing is performed by Drosha and Pasha, an RNase III endonuclease and a double-
stranded RNA binding protein respectively 
111;112
.  The pre-miRNA is transported from the 
nucleus to the cytoplasm by a molecule named Exportin-5.  It is here that the pre-miRNA is 
cleaved by an RNase III enzyme called dicer to form mature miRNA.  Mature miRNA is then 
loaded onto a multi-protein complex called an RNA-induced silencing complex (RISC) 
which acts as a guide for the miRNA.  RISC binds to the 3’ untranslated region of mRNA by 
imperfect base pairing.  Once bound, the RISC molecule causes gene silencing by either 
cleaving the target mRNA, or by inhibiting the translational process 
108
.   
 
The primary target recognition determinant known as the seed region is only 7/8 nucleotides 
in length, thus a single miRNA can potentially regulate hundreds of gene targets 
113;114
.  It is 
surprising that miRNAs have only recently been discovered considering that they also 
comprise one of the more abundant classes of gene regulatory molecules 
110
. 
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MiRNAs are grouped into families if they share an identical sequence in the seed region.  As 
such, those from the same family bind to and regulate the expression of essentially the same 
set of target mRNAs.  
 
Researchers at the University of Manchester and the Wellcome Trust Sanger institute have 
created a comprehensive online database of all the miRNAs discovered to date.  This is a 
rapidly developing area of research as evidence by the exponential growth in the number of 
mature miRNAs identified over the past few years.  The most recent database was uploaded 
in April 2011 (miRBase 17 release) and contains 16,772 mature miRNAs originating from 
over one hundred different species.  This compares to only 703 mature human miRNAs 
reported in the miRBase 13 release in March 2009 
115-118
. 
 
Computational approaches can be used to identify regulatory targets of miRNAs.  If we know 
the functional role of these targets, this provides clues to the function of the miRNA 
108
.  
However, there are few mRNA molecules with near-perfect complementary base pairs to 
miRNAs, thus making false positives common.  Accordingly, prediction algorithms can only 
provide a list of their likely targets but cannot be assumed to be correct, and need to be 
followed up with experimental evaluation 
110
. 
 
 
 
1.4.2 MicroRNAs and human cancer 
 
The potential of miRNAs to act as biomarkers for disease has also been identified.  Unlike 
most other biomarkers currently available, this group of molecules appears to be disease and 
cell type specific 
119
.  PDAC is a disease resulting from epigenetic alterations, and 
conceivably has its own specific miRNA expression profile.  Their central role in cellular 
regulation, as well as their inherent stability especially in patient serum at room temperature 
represent further reasons why these molecules would make useful biomarkers 
120
.    
 
Lu and colleagues 
121
 performed miRNA expression profiling for different types of human 
cancers.  They described that miRNA profiles not only revealed the developmental lineage of 
the tumour but also the state of differentiation.  In general, they observed miRNA expression 
to be down-regulated in tumours compared to normal tissues.  Messenger RNA (mRNA) 
43 
 
profiling was also carried out in conjunction with these experiments but mRNAs were highly 
inaccurate in differentiating samples. 
 
Several miRNAs have been labelled as oncomiRs due to their capacity to down-regulate 
tumour suppressor genes and promote tumour oncogenes.  Alternatively, other miRNAs have 
been shown to negatively regulate oncogenes, for example miR-15 down-regulates BCL2.  
Therefore, gene therapies using the latter may be an effective approach to inhibiting 
oncogenes and blocking tumour progression 
109
.   
 
 
 
1.4.3 The microRNA-29 family 
 
An important area of research which has not been addressed to date is the involvement of 
miRNAs in the regulation of pancreatic stellate cells.  Identifying miRNAs which control the 
behaviour of PSCs is essential, since this may hold the key to reversing their activity, thus 
inhibiting the growth and dissemination of cancer cells.  
 
Indications that miRNAs are important in regulating PSCs emerge from studies relating to 
liver fibrosis.  Roderberg and colleagues 
122
 recently profiled miRNAs in mouse livers made 
fibrotic through carbon tetrachloride treatment and bile duct ligation.  They found several 
miRNAs to be differentially expressed including all three members of the miR-29 family.  In 
vitro analyses of resident hepatic cells revealed that miRNA-29 levels were normally 
expressed at very high levels in hepatic stellate cells, when compared with hepatocytes, 
Kupffer cells, and endothelial cells. 
 
In subsequent experiments, isolated Hepatic stellate cells (HSC) were activated with TGFβ or 
lipopolysaccharide, which significantly reduced miRNA-29 levels through NFκB signalling.  
Up-regulation of this miRNA was also associated with a reduction in the expression of the 
ECM collagen genes, Col1a1, Col4a5, and Col5a3.  This suggests that activated HSCs 
increase their secretion of collagen through the down-regulation of miRNA-29.  This notion 
is further supported by their serum analyses showing miRNA-29 to be reduced in patients 
with advanced liver cirrhosis compared to healthy controls or patients with early cirrhosis. 
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HSCs and PSCs not only appear the same morphologically, but also possess similar functions 
including their mediation of fibrosis through production of collagen and other ECM proteins.  
Transcriptomic analysis of the two cell types displayed similar gene expression profiles, 
although distinct differences in expression patterns were observed 
113
.  The similarities 
between these two cell types represent further indications that miRNAs are important in the 
regulation of PSCs. 
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CHAPTER 2: 
STUDY AIMS 
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2.1 Study aims 
 
1. To isolate and characterise pancreatic stellate cells derived from tissue specimens of 
patients with a variety of pancreatic diseases. 
 
2. To conduct a preliminary investigation to compare microRNA-29 expression between 
cancer-derived and inflammatory-derived primary pancreatic stellate cells.  
 
3. To cryopreserve stocks of pancreatic stellate cells and other pancreatic stromal cell 
types for use in future experiments including microRNA analysis. 
 
4. To determine optimal experimental techniques for the isolation and characterisation of 
pancreatic stellate cells to provide guidelines for future researchers in Dr Costello’s 
laboratory. 
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CHAPTER 3: 
MATERIALS & METHODS  
48 
 
3.1 Cell lines and cell culture 
 
Four human Pancreatic ductal adenocarcinoma (PDAC) cell lines (MIA PaCa-2, Panc-1, 
BXPC-3, Suit-2) were cultured in RPMI 1640 media (Sigma, Poole, UK) supplemented with 
10% FBS (PAA, Pasching, Austria), 1% L-glutamine (200mM) and 1% penicillin-
streptomycin (100U/mL) (Sigma, Poole, UK).  Primary PSCs were cultured in IMDM media 
(Sigma, Poole, UK) supplemented with FBS, L-glutamine and penicillin-streptomycin 
solution as above. 
We also received an immortalised pancreatic stellate cell line named ‘RLT-PSC’ as a kind 
gift from Dr Ralf Jesenofsky 
89
, University of Heidelberg, Germany.  These cells were 
isolated from human pancreatic tissue affected by chronic pancreatitis using an outgrowth 
method.  They were then characterised and immortalised by transfection with SV40 large T 
antigen and human telomerase (hTERT).  These cells were cultured in DMEM/F-12 + 
Glutamax media (Invitrogen, Paisley, UK) supplemented with 10% FBS, 1% L-glutamine 
(200 nM) and 1% penicillin-streptomycin solution (100U/mL). 
 
All cell lines were cultured as a monolayer in 10mL media in T75 flasks (Fisher Scientific, 
Loughborough, UK) at 37°C in 5% CO2.  Once the cells reached 80-90% confluence they 
were washed with Dulbecco’s PBS and passaged using 3mL of Trypsin-EDTA solution 
(0.5% porcine trypsin, 0.2% EDTA in Hank’s Balanced Salt Solution with Phenol Red).     
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3.2 Sample collection 
 
3.2.1 Protocols for sample collection 
We requested protocols for stellate cell isolation from Dr Phoebe Phillips, a postdoctoral 
fellow with expertise in pancreatic stellate cell culture at the University of New South Wales, 
Australia.  These were kindly sent by electronic mail, and formed the basis of the explant 
method, that we adopted to isolate activated pancreatic stellate cells from pathological 
pancreatic tissue. 
The Liverpool Experimental Cancer Medicine Centre (LECMC) had formerly established 
protocols for the collection of human pancreatic tissue following surgical resection at the 
Royal Liverpool University Hospital.  These procedures were performed to the standard of 
good clinical laboratory practice (GCLP). 
 
The protocols received from Dr Phillips for stellate cell isolation were not compatible with 
the sample collection methods already in place.  The previous Departmental standard 
operating procedure (SOP) stated that the resected pancreatic specimen should be transported 
from theatre to the Pathology Department in a dry specimen pot with no specified urgency.  
Alternatively, the PSC isolation protocol emphasised the importance of both, keeping the 
specimen at freezing temperatures during transportation, and placing the tissue into culture as 
soon as possible.  Therefore, in compliance with GCLP, the SOP for the collection and 
transport of pancreas tissue samples from theatre was adjusted accordingly. 
 
3.2.2 Kit building 
The sample collection methods already in place utilised kits to obtain tissue from patients for 
research purposes.  Each kit consisted of around 40 components including micro-centrifuge  
tubes, cryotubes, syringes, needles, consent forms and a urine pot.  Samples of blood, urine, 
and pancreatic juice, along with tru-cut biopsies and pieces of normal and tumour tissue 
excised during surgery were obtained from the patient.  Tissue samples were also gathered 
from organs surrounding the pancreas such as the duodenum and common bile duct. 
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In order to collect extra human tissue for PSC culture, a new type of kit was designed with 
three additional components to those contained in the regular pancreas collection kit.  The 
new components comprised of two cryotubes, one for snap freezing pancreatic tissue in liquid 
nitrogen, and another containing ‘RNA later’ reagent to preserve tissue for RNA analysis at a 
later date.  Thirdly, a viable sample sticker with a printed bar code was also added to the kit 
components.  If PSCs were successfully cultured from a pancreas tissue sample then this 
sticker would be affixed to my laboratory notebook, corresponding with any information 
regarding subsequent stellate cell culture.  All kits manufactured were recorded on the 
Laboratory information management system (LIMS) system and were subject to quality 
assurance checks in compliance with GCLP regulations.  Each of the kit components was 
labelled with a unique barcode so that their storage locations could be tracked.     
 
3.2.3 Sample collection day  
In preparation for a sample collection day, PBS was poured into 1 litre glass bottles which 
were sterilised by autoclaving.  Plastic specimen pots which were to be used to contain the 
specimen and PBS during transportation were also sterilised.   This involved washing with 
bleach, followed by rinsing with water to wash the bleach off, and a subsequent wipe with 
70% ethanol.   
On the morning of a resection a 1 litre batch of sterile PBS was poured into an empty 
specimen pot and stored in the GCLP freezer room refrigerator at 4°C.   Throughout the rest 
of the day, we awaited a telephone call from the theatre staff to inform us whether the tissue 
specimen was soon to be, or had already been resected.  Occasionally, we were notified that 
the sample was non-resectable due to local advancement or distant metastases.  If the sample 
was ready for collection, the specimen pot was placed into a rubber ice bucket containing ice 
cold freezer bags and transported from the GCLP freezer room to theatre, along with 2 
cryotubes (one for snap freeze and one for RNA later) and a liquid nitrogen container. 
On arrival in theatre the resected specimen was transferred from a dry pot into ice cold PBS.  
It was important to minimise the amount of time that the specimen was left in the dry pot by 
arriving to theatre as quickly as possible after the sample was declared ready for collection. 
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A telephone call was made to the Pathology Department informing them that the resection 
had taken place and that we would soon arrive there with the specimen.  The ice bucket 
containing the specimen immersed in ice cold PBS was transported to Pathology as quickly 
as possible. 
As long as the pathologist deemed there to be a sufficient amount of tissue for histological 
diagnosis, surplus tissue could be excised from the specimen for research purposes.  If this 
was the case, the pathologist would dissect a fibrous piece of cancerous or inflamed tissue.   
The pathologist sliced the dissected tissue sample into two pieces.  The first was destined for 
snap freezing in a Dewar liquid nitrogen container, and the second was immersed into a 
Falcon tube containing 20mL of sterile ice cold PBS supplemented with 1% Pencillin-
Streptomycin solution.  A tissue sample was considered to be fibrous if it sank to the bottom 
of the Falcon tube.  Unwanted excess fatty tissue would cause it to float in the PBS. 
The sample to be snap frozen was wrapped in aluminium foil, inserted into a cryotube and 
immersed in liquid nitrogen.  This cryotube was temporarily stored in the Dewar container 
until it was transferred to the -150°C freezer in the GCLP facility biobank later that day. 
The other piece of tissue was transported to the primary culture laboratory for processing.  
This was then further dissected into three pieces, the first for PSC outgrowth, the second 
immersed in ‘RNA later’ reagent, and the third immersed in 4% formalin (Sigma, Poole, UK) 
to be later examined by Haematoxylin and Eosin staining.   
The tissue destined for ‘RNA later’ reagent was diced into tiny pieces, approximately 1-
2mm
3 
in size before being dropped into the solution.  This cryotube was stored in the GCLP 
facility at 4°C overnight, and then transferred to -80°C the following day.  The freezer 
locations for both the snap freeze and ‘RNA later’ cryotubes were recorded on the LIMS 
system. 
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3.3 Pancreatic stellate cell outgrowth 
 
The dissected tissue sample was swiftly transported from Pathology to our laboratory, where 
it was diced into tiny pieces (<1mm
3
) using a sterile scalpel and sterile tweezers (Sigma, 
Poole, UK).   
The culture medium used for stellate cell outgrowth was Iscove’s modified Dulbecco’s 
medium (IMDM) (Sigma, Poole, UK) supplemented with 20% FBS (PAA, Pasching, 
Austria), 1% L-glutamine (2mM), and 1% penicillin-streptomycin solution (100U/mL) 
(Sigma, Poole, UK).   
Half a millilitre of IMDM media was added to a 40 mm diameter petri dish.  Five pieces of 
diced tissue were placed into the dish with sufficient space between them, using sterile 
tweezers.  The dish was then placed into the incubator for culture at 37°C in 5% CO2.  Care 
was taken when transporting it to the incubator, ensuring that it was held flat to prevent the 
tissue pieces from being displaced.  This process was repeated using the remainder of the 
diced tissue sample.  
Over the next few days the dishes were monitored for any sign of contamination such as 
turbid media.  In the absence of obvious infection, a further 0.5 mL of media was added to 
each dish after 3 days of culture.  From here onwards, media was exchanged once every 3 
days.  
According to Dr Phillip’s protocols, PSCs were expected to grow out from the tissue pieces 
after 1-2 weeks of culture.  Moreover, following the initiation of PSC outgrowth in the dish, 
it was recommended that the tissue pieces should be removed as soon as ‘empty zones’ began 
to appear in the spaces immediately surrounding them.  The term ‘empty zone’ simply 
referred to an area lacking in cell growth.  
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3.4 Pancreatic stellate cell culture 
 
After reaching confluence in the dish, stellate cells were passaged into a T-25 or T-75 flask 
(Fisher Scientific, Loughborough, UK).  A volume of 1mL Trypsin-EDTA solution (0.05%, 
0.02%) was added to the petri dish which was incubated for 3 min.  After this time period the 
trypsin was neutralised with 2mL IMDM media supplemented as described above.   
Occasionally cells would cease to grow before they reached full confluence in the petri dish.  
In my experience, only cells with a greater confluence than 50% would manage to survive 
and proliferate after propagation into a new flask.   
IMDM media used to culture primary cells in T25/T75 flasks was supplemented with 10% 
instead of 20% FBS.  Cells that reached confluence in a T25 were passaged using 1.5mL 
trypsin, and incubated for 3min as above.  Trypsin was neutralised with 3.5mL media.  Three 
millilitres of trypsin was used to passage cells cultured in a T75 flask, and this was 
neutralised with 7mL of media. 
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3.5 Pancreatic stellate cell cryopreservation 
 
Once stellate cells reached confluence in a T75 flask (usually passage 2) they were ready for 
cryostorage.  Cells were washed twice with 10 mL PBS.  Three millilitres of trypsin was 
added and the flask incubated at 37°C for 2-4 min.  The degree of cell detachment was 
determined by observation under the microscope, and the flask was tapped several times to 
aid detachment.  Seven mL of IMDM culture medium was added to stop the action of trypsin.  
The cell suspension was mixed by gentle pipetting, and the sides and surface of the flask 
were rinsed.  The suspension was transferred to a falcon tube and centrifuged at 1500 rpm, 
4°C for 5 min.  All of the supernatant was removed and the tube flicked several times to 
break up the cell pellet.  A solution consisting of 5% DMSO dissolved in IMDM media (20% 
FBS) was removed from ice, and 1.5mL of this was added to the cell pellet.  This was mixed 
by gentle pipetting.  The resulting solution was transferred into a cryotube and kept on ice.  
The PSCs were stored at -80°C for 24 h, before being transferred to the -150°C freezer 
located in the GCLP facility.  The location of all cryopreserved cells was logged onto the 
LIMS. 
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3.6 Characterisation of Pancreatic stellate cells by Immunofluorescence staining 
 
3.6.1 Immunofluorescence experiment protocol 
 
Glass coverslips 13mm in diameter (Fisher Scientific, Loughborough, UK) were sterilised by 
autoclaving in advance of the immunofluorescence staining experiment.  They were 
subsequently stored in a petri dish containing 70% ethanol solution so as to maintain their 
sterility. 
Mounting medium was also prepared in advance in the following way.  Six grams of 
glycerol, 2.4g Mowiol 4-88 (Sigma, Poole, UK), 6mL ddH20, and 12mL 0.2M Tris buffer pH 
8.5 was mixed for 12 h on the shaker.  This was left to sit for 2 h.  The mixture was incubated 
at 50°C for 10 min and then centrifuged at 5000g for 15 min.  Finally, the supernatant was 
removed, aliquoted and freezed at -20°C until use. 
When stellate cells reached confluence in a T75 flask they were trypsinised.  Three millilitres 
of the resultant 10 mL cell suspension were kept in the flask and topped up with media.  The 
other 7 mL was transferred into a 15 mL Falcon tube, and cell clumps removed by gentle 
pipetting.  Twenty five microlitres of this cell suspension was pipetted into a haemocytometer 
chamber, cells were counted, and the number of cells per mL calculated.   
Whilst working in the cell culture hood, coverslips were transferred into the wells of a 24 
well plate using sterile forceps.  One millilitre of the cell suspension at the appropriate cell 
density was dispensed into each well.  Cell densities varied according to cell type but ranged 
between 3x10
4
 and 8 x10
4
 cells per well. 
Immortalised PSCs and PDAC cell lines were plated at lower cell densities to the primary 
stellate cells due to their more rapid rate of growth.  Cells were left in the incubator to 
proliferate and adhere properly to the coverslips. 
Forty-eight hours later, cells were rinsed twice with PBS before fixation in 4% formalin 
(Sigma, Poole, UK).  Fixation was achieved through the addition of 1 mL of formalin 
solution per well, and incubation for 20-30 min at 4°C.  
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The formalin was aspirated and cells were rinsed with PBS.  Cells were permeabilised by 
incubating with PBS+0.5% Triton X-100 (Sigma, Poole, UK) for 3-5 min at 4°C.  Three 
washes, each lasting 5 min, were carried out with PBS whilst gently shaking the plate. 
All blocking solutions were prepared using PBS.  Goat serum (Invitrogen, Paisley, UK) 
diluted to a concentration of 10% was usually used for blocking.  However, when staining for 
vimentin expression, BSA at a concentration of 2% was utilised instead because our vimentin 
antibody is raised in goat species.  Protein aggregates were removed by passing the blocking 
solution through a 0.2µm filter.  Blocking was carried out for at least 1 h using 1mL per well, 
ensuring coverslips were entirely covered. 
All antibodies were diluted in blocking solution.  Depending on which agent was used for 
blocking, goat serum was reduced from 10% to 2% for the antibody incubation step, whereas 
BSA was reduced from 2% to 1% for the antibody incubation step.  Prior to treatment with 
the antibody, the plate lid was labelled and parafilm adhered to the lid.  Twenty-five 
microlitres of antibody solution was pipetted onto the parafilm over each corresponding well. 
Coverslips were lifted out from the wells using fine tip forceps, and then laid cell face down 
onto the drop of antibody solution.  Care was taken to make sure that the entire surface of the 
coverslip was immersed in the drop of fluid.  The plate lid was left in a humidified chamber 
(plastic container containing paper towels soaked in warm water) for 1 h at room temperature 
or alternatively overnight at 4°C.   
Coverslips were transferred back into the wells of the 24-well plate and washed 3 times with 
PBS for 5 min each with gentle shaking. 
Secondary antibody treatment was carried out using the same technique as for the primary.  
From this point onwards the coverslips were protected from the light whenever possible using 
aluminium foil to cover the plate. 
Subsequent to another 2 washes lasting 5 min each, the coverslips were treated with DAPI 
(4′,6-Diamidino-2-phenylindole dihydrochloride) solution (Sigma, Poole, UK) for 5 min and 
then placed back into PBS.  DAPI was applied at a concentration of 0.5 µg/mL. 
Five microlitres of Mowiol 4-88 (Sigma, Poole, UK) mounting medium was dispensed onto a 
glass slide (VWR, Lutterworth, UK).  The coverslip was lifted from the 24 well plate and 
excess moisture aspirated by gentle contact against a paper towel.  The coverslip was then 
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layered slowly onto the drop of mounting medium cell face down, whilst ensuring that no 
bubbles of air were trapped beneath the coverslip.   
Mounting medium was left to set for a minimum of 3 h.  Glass slides were stored at 4°C in 
the dark. 
Due to the delicate nature of this procedure, occasionally a glass coverslip would be dropped 
whilst transferring them back and forth with forceps.  In such as scenario one must then 
determine which side of the coverslip has the adherent cells.  This can be identified by one of 
the following two methods.  Firstly, if one hand is used to hold the coverslip, the other hand 
is used to scratch the surface of the coverslip gently with forceps, observing whether any cells 
are removed in the process.  Alternatively, the coverslip can be transferred back into the well 
of the 24 well plate and examined under the microscope.  If the coverslip happens to be cell 
side up then the cells growing on the coverslip will focus at a different magnification to the 
cells growing directly on the plate around the coverslip.  
The antibodies used to stain for stellate cells are listed in Table 3.1 below. 
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Antibody 
 
Species raised in Marker  Supplier 
GFAP  Rabbit polyclonal Stellate cell / astrocyte Abcam, Cambridge, UK 
GFAP  Rabbit polyclonal Stellate cell / astrocyte DAKO, Stockport, UK 
Desmin Rabbit polyclonal Stellate / smooth muscle 
cell 
Abcam, Cambridge, UK 
Desmin  Mouse monoclonal Stellate / smooth muscle 
cell 
DAKO, Stockport, UK 
Alpha smooth muscle 
actin 
Mouse monoclonal Stellate cell / 
myofibroblast 
Abcam, Cambridge, UK 
Vimentin Goat polyclonal Mesenchymal cell Santa Cruz Biotech, 
USA 
Pan-cytokeratin Mouse monoclonal Epithelial cell  Abcam, Cambridge, UK 
Isotype control mouse Normal mouse IgG Santa Cruz Biotech, 
USA 
Isotype control rabbit Normal rabbit IgG Santa Cruz Biotech, 
USA 
Alexa fluor 488  mouse Green fluorescent tag Invitrogen, Paisley, UK 
Alexa fluor 488  rabbit Green fluorescent tag Invitrogen, Paisley, UK 
 
Cy3  
 
mouse 
 
Red fluorescent tag 
Jackson 
ImmunoResearch, West 
Grove, USA 
 
Cy3 
 
rabbit 
 
Red fluorescent tag 
Jackson 
ImmunoResearch, West 
Grove, USA 
 
Cy3 
 
goat 
 
Red fluorescent tag 
Jackson 
ImmunoResearch, West 
Grove, USA 
Table 3.1 Antibodies used for the characterisation of stellate cells in this project. 
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3.6.2 Immunofluorescence image analysis 
 
Immunostained cells were visualised using the 100x oil immersion lens of a fluorescent 
microscope (Nikon TE 300).  Images were captured with an attached Zeiss camera. 
The coverslips were wiped using a cotton bud soaked in analytical reagent grade methanol.  
A drop of Carl Zeiss Immersol 518N immersion oil (Fisher Scientific, Loughorough, UK) 
was placed onto each coverslip.  It was imperative that slides removed from the refrigerator 
were allowed to warm to room temperature before observation under the microscope to avoid 
condensed water mixing with the immersion oil.   
In order to observe the cells, the slide was slotted upside down on the microscope platform, 
and the lens raised high enough so that it gently touched against the coverslip. 
Simple PCI 6 software was utilised for image interpretation and processing.  Images were 
recorded in ‘tif’ format and were later converted to ‘png’ files using ImageJ software.  Gain, 
exposure and binning settings were constant between cells stained within the same 
immunofluorescence experiment to allow for accurate comparisons.  However, these 
measures could be adjusted between different experiments.  
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3.7 MicroRNA-29 analysis 
 
3.7.1 Cell plating and TGFβ treatment 
 
Primary PSCs, RLT-PSCs and the BXPC3 cancer cells were seeded in 6 well plates as shown 
in the tables below.  Cells were starved in 2% FBS and either: 
 Stimulated for 48 h with 20ng/mL recombinant human TGF-β or 
 Left untreated for 48 h 
They were lysed immediately after this treatment and underwent RNA purification. 
 
Plate 1 
 
Pt 1 Stellate with TGF-β 
 
 
Pt 2 Stellate with TGF-β 
 
 
RLT PSC with TGF-β 
 
Pt 1 Stellate without TGF-β 
 
 
Pt 2 Stellate without TGF-β 
 
 
RLT PSC without TGF-β 
 
Plate 2 
 
BXPC3 cancer cell line with 
TGF-β 
  
 
BXPC3 cancer cell line 
without TGF-β 
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3.7.2 RNA purification 
 
RNA molecules ranging in size from 18 to 200 nucleotides were purified from cultured cells 
using the miRNeasy mini kit (Qiagen, Crawley, UK).  The cells were lysed directly in the 6 
well plates using 700 µl of QIAzol lysis reagent.  A cell scraper was used to aid transfer of 
the lysate into microcentrifuge tubes (Eppendorf, Cambridge, UK).  From this point onwords, 
reactions were carried out on ice unless otherwise stated.    
The lysates were homogenised by vortexing for 1 min, then allowed to stand on the benchtop 
at room temperature for 2-3 min.  One hundred and forty microlitres of chloroform was added 
to each tube and shaken vigorously for 15 s before being left on the benchtop again for 2-3 
min.  This suspension of lysate mixed with chloroform was centrifuged for 15 min at 13,000 
rpm at 4°C, separating the sample into 3 phases: an upper, colourless, aqueous phase 
containing RNA; a white interphase; and a lower, red, organic phase.  The upper aqueous 
phase was pipetted into a new eppendorf tube.  One and a half volumes of 100% ethanol was 
added to each tube and mixed thoroughly by pipetting.  Continuing without delay, 700 μl of 
the sample was transferred into an RNeasy Mini spin column in a 2 mL collection tube.  This 
was centrifuged at 10,000 rpm for 15 s at room temperature and the flow-through discarded.   
DNase digestion was also performed.  Three hundred and fifty microlitres of miRNeasy mini 
kit buffer RWT was pipetted into the RNeasy Mini spin column and centrifuged for 15 s at 
10,000 rpm.  The flow-through was discarded.  Eighty microlitres of DNase I incubation mix 
was pipetted directly onto the RNeasy Mini spin column membrane, and the tube placed on 
the benchtop for 15 min.  Three hundred and fifty microlitres of the RWT buffer was then 
pipetted into the RNeasy Mini spin column which was centrifuged for 15 s at 10,000 rpm.  
The flow-through was discarded. 
 
Five hundred microlitres of miRNeasy mini kit RPE buffer was pipetted onto the RNeasy 
Mini spin column which was centrifuged for 15 s at 10,000 rpm to wash the column.  The 
flow-through was discarded.  Another 500 μl of RPE buffer was added to the RNeasy Mini 
spin column and this time centrifuged for 2 min to dry the RNeasy Mini spin column 
membrane.  This ensured that no ethanol was carried over during RNA elution which could 
interfere with downstream reactions.   
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Following centrifugation, the RNeasy Mini spin column was removed from the collection 
tube containing flow-through and placed into a new 2 mL collection tube and centrifuged at 
full speed for 1 min.  This step eliminated any possible carryover of Buffer RPE.  The 
RNeasy Mini spin column was transferred to a new 1.5 mL collection tube.  Forty microlitres 
of RNase-free water was pipetted directly onto the RNeasy Mini spin column membrane and 
the tubes centrifuged for 1 min at 10,000 rpm.  This resulted in elution of RNA and the tubes 
were stored at -80°C. 
 
 
2.7.3 Reverse Transcription 
 
 
RNA was reverse transcribed into cDNA using the miScript reverse transcription kit (Qiagen, 
Crawley, UK). 
 
The purified RNA samples and miScript reverse transcriptase mix were thawed on ice.  
RNase free water and 5x miScript RT Buffer were thawed at room temperature.  The 
individual solutions were mixed and centrifuged briefly to collect residual liquid from the 
sides of the tubes.  
 
The reverse transcription master mix was prepared on ice.  The 5x RT buffer (containing 
Mg
2+
, dNTPs and primers), RNase free water and reverse transcriptase mix were added 
together in 0.5 mL PCR tubes.  The resulting solutions were mixed by gently flicking the 
tubes.  The template RNA (up to 1 µg) was then added and the tubes were centrifuged briefly 
at 5,000 rpm.  The mixtures were then incubated for 1 h at 37°C followed by 5 min at 95°C.   
 
After this incubation the quantity of cDNA in each sample was determined using a ND-1000 
nanodrop spectrophotometer along with ND1000 v3.5.2 software.   
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3.7.4 Real-time PCR 
 
Mature microRNA was quantified by real-time PCR using the miScript SYBR Green PCR 
kit, miScript Primer Assays, and miScript PCR control set (Qiagen, Crawley, UK).   
Before starting the procedure the 10x miScript Primer assays and PCR control set primers 
were thawed on ice.  The primers were reconstituted by centrifuging the vial briefly, then 
adding 550 µl of TE buffer.  The resulting solution was mixed by vortexing.   
 
The template cDNA was also thawed on ice.  Each sample was diluted with TE buffer to give 
a concentration at which it was possible to load 1-3 ng in a volume of less than 5 μl.  These 
volumes were calculated according to the cDNA concentrations detected by the nanodrop.  
 
The 2x QuantiTect SYBR Green PCR Master Mix was thawed along with the 10x miScript 
Universal Primer and RNase-free water. The individual solutions were mixed by gently 
inverting the tubes. 
 
Twenty-five microlitres of the SYBR green master mix and 5 µl of the universal primer were 
pipetted into the wells of the 96 well plate giving a volume of 30 μl per well.  Variable 
volumes of the RNase free water were then added to the wells, followed by 5 µl of the 
specific primer or PCR control primer (RNU6B is recommended).   
 
Finally, the cDNA was added to the wells, and the plate was sealed with a plastic sheet and 
centrifuged briefly.  It was placed into the plate holder of the real-time cycler (Roche 
Lightcycler 480) and programmed as shown in Table 3.2 below.  Real-time PCR data was 
analysed using LightCycler 480 Software, Version 1.5. 
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Step Time Temperature 
 
PCR 
Initial 
activation step 
 
 
 
15 min 
 
 
95ºC 
3-step cycling: 
 
  
Denaturation 15 s 94ºC 
 
Annealing 30 s 55ºC 
 
Extension 30 s 70ºC 
Cycle number 45 cycles 
 
 
Table 3.2 PCR programme used for the amplification of micro-RNAs 
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CHAPTER 4:   
RESULTS 
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4. 1 Sample collection and primary cell culture 
 
4.1.1 Sample collection from theatre 
 
A significant delay was experienced during the first sample collection.  Having arrived at the 
Pathology Department with a Whipple’s resection specimen, there were no pathologists 
available to process the sample.  Almost an hour had passed before any tissue had been 
dissected.  During this wait the resected tissue remained in a specimen pot containing PBS 
which gradually warmed to room temperature.  The dissected tissue was transported back to 
the laboratory and diced before being plated into culture in a 6-well plate.  This plate was 
observed for 2 weeks before it was discarded due to the absence of cell outgrowth.   
In order to reduce the delays experienced during the first sample collection, arrangements 
were made with the Pathology Department to ensure that future resected samples for the 
purposes of stellate cell research would be attended to immediately upon arrival from theatre.  
As part of these new arrangements, the Pathology Department requested notification of any 
resection from which pancreatic cells were to be cultured, at least 24 h in advance.  Also, a 
second notification was to be made to the on-call pathologist during the operation, informing 
them that the sample would arrive to their Department within 30 min.  
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4.1.2 Primary cell culture 
 
During the collection of the second sample, the time taken to transfer resected tissue from 
theatre and into culture was significantly reduced to approximately 30 min.  Three 6-well 
plates were prepared, each containing 5 pieces of diced pancreatic tissue per well.     
After 1 week in culture, spindle and stellate-shaped cells began to grow out from the tissue in 
some of the wells.  Cell growth continued for one more week before many of the outgrowing 
cells died or ceased proliferating.  Dr Phillips’ protocols for stellate cell culture (See Section 
3.4 Materials and Methods) stated that the appearance of ‘empty zones’ in the space 
immediately surrounding the tissue signifies the appropriate time to remove them from 
culture.  However, the appearance of such ‘empty zones’ was difficult to interpret.  
Moreover, protocols from Dr Phillips lacked any information regarding the time period after 
which these ‘empty zones’ are expected to appear.   
Many of the outgrowing cells died after only one week of proliferation, and it was 
hypothesised that this could have been avoided through earlier removal of tissue.  This is 
because tissue left in the culture plate for too long could possibly have become necrotic thus 
inhibiting surrounding growth.  In order to test this hypothesis, the tissue was removed from 
one of the few wells which still contained proliferating cells, and the cells were extracted into 
the well of a new 6-well plate.  These cells were observed 24 hours later.  Only a few of the 
extracted cells adhered to the plate and began to proliferate.  Subsequently, a few days later 
all the cells had died and therefore the plate was discarded.  The reason for the cell death may 
have been that the trypsin reagent was poorly tolerated by the primary cells.  Alternatively, 
there may have been insufficient cell numbers to allow for proliferation in the new dish.    
After 3 weeks in culture, cells had once again begun to proliferate in around half of the wells.  
It was now imperative to determine the appropriate time period after which to remove the 
tissue pieces from culture, and also when to extract the cells from the well.  Hence, over the 
coming weeks tissue was removed at different times in the various wells and the effect on cell 
viability was observed by carefully examining the cells daily using a light microscope.  
Rarely did a clear space or ‘empty zone’ appear between the tissue and cells.  In fact, several 
wells became confluent with cells and still no space appeared adjacent to the tissue.  Hence, 
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the appearance of ‘empty zones’ next to the tissue did not prove to be a useful guide for when 
to remove the explanted tissue. 
After over a month in culture, from a total of eighteen wells for this patient sample, only 
wells 3 and 5 were successfully passaged into cell culture flasks.  In addition to removing 
tissue pieces too late, it appeared that cell death occurred if tissue was removed too early, 
perhaps related to a reduction in the quantities of growth factors which accompanies the 
removal of explanted tissue.  Furthermore, as well as removing cells too early from culture as 
mentioned above, leaving cells to culture in the wells for too long also led to fungal 
contamination in some cases.   
The correct balance was achieved whereby tissue removal was carried out as soon as cell 
proliferation had ceased for more than 2 weeks.  This was measured by observing the cells 
daily and monitoring the edges of the growth perimeter, which were indicated on the plate lid 
using marker pen.  Also, transferring the cells to a new flask or passaging of cells was only 
performed once the well was more than 50% confluent with cells. This seemed to facilitate 
sufficient proliferation in the T25 flask into which the cells were transferred.   
The use of 6-well plates for primary culture as recommended by Dr Phillips’ protocols was 
later discontinued.  Although they are easier to handle during transfer in and out of the 
incubator, the appearance of fungal contamination in one of the plate wells would swiftly 
spread to the other wells.  Instead, 40mm diameter petri dishes were utilised as pictured in 
Figure 4.1. 
 
 
Figure 4.1  A 40mm diameter petri 
dish showing five pieces of tissue, 
as they appear immediately after 
placing in culture.  
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4.1.3 Primary cultured cell passage 
 
In Dr Costello’s laboratory the reagent typically used to detach adherent cells from the cell 
culture plate is Trypsin-EDTA solution, specifically comprising of 0.5% porcine trypsin and 
0.2% EDTA.  This solution causes minimal cell death when used to passage pancreatic 
cancer cell lines.  However, when utilised for the passage of primary cultured cells it led to 
loss of viability and reduced growth. 
Various types of Trypsin-EDTA reagent are available for purchase, each differing in their 
concentration of Trypsin and EDTA.  Other types of cell dissociation buffer are also available 
which utilise different digestive enzymes, such as collagenase buffer, or use no digestive 
enzymes at all.  
Several research groups have previously reported their success in establishing primary 
cultures of human PSCs 
89;123-125
.  While they  have mentioned the use of trypsin for cell 
passage, they have not specified the concentrations of Trypsin and EDTA contained within 
these reagents 
89;123-125
.    
Therefore, a number of different types of cell dissociation reagent were trialled in order to 
elucidate which of these would be best tolerated during primary cell passage. The results are 
summarised in Table 3.1, and described below.  Consistently in these experiments, cells 
cultured in T75 flasks were passaged with 3 mL of the particular cell dissociation reagent and 
incubated for 3 min.  Cell viability was then observed 24 h later.  
Trypsin-EDTA solution containing 2.5% Trypsin and 0.5% EDTA was recommended by our 
colleagues in Dr Andrea Varro’s Physiology Research Group at the Liverpool Cancer 
Research UK Centre.  They use this reagent to dissociate adherent primary gastric 
myofibroblasts, cells which possess similar characteristics to primary activated PSCs.  
Unfortunately, when this reagent was used to dissociate the primary cells, it resulted in even 
greater proportions of cell death compared with the trypsin used as standard in Dr Costello’s 
laboratory.  
Gibco cell dissociation buffer, an enzyme free reagent was also experimented with.  When 
this was applied to the primary cells for passage it resulted in fewer dead cells than Trypsin-
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EDTA (2.5% Trypsin 0.5% EDTA).  However, in comparison with Trypsin-EDTA (0.5% 
Trypsin 0.2% EDTA), there was a greater proportion of cell death. 
The fourth and final dissociation agent that was trialled for cell passage was a weaker form of 
Trypsin-EDTA reagent containing only 0.05% Trypsin and 0.02% EDTA.  This reagent was 
recommended by Dr Ralf Jesenofsky of the University of Heidelberg, who utilises this 
reagent for passage of both primary cultured rat PSCs and the immortalised PSC line (RLT-
PSC) developed by their research group.  Of all the types of dissociation reagents that were 
investigated, this was the best tolerated reagent, with minimal cell death occurring during 
passage.  Despite its low concentrations of trypsin and EDTA, cells dissociated from the 
plastic plate within 2-4 minutes of incubation, as was observed when the other reagents were 
used. 
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Product name / 
supplier 
Components Passaged cells Approximate cell 
death 
 
Trypsin-EDTA solution 
1x (Sigma, Cat No: 
T3924) 
0.5% porcine trypsin, 
0.2% EDTA, 4Na per 
litre of Hanks′ Balanced 
Salt Solution with 
phenol red 
 
 
CP 07.02.11 Dish 11 
 
10% 
 
Trypsin-EDTA solution 
1x (Sigma, Cat No: 
T4049) 
2.5% porcine trypsin, 
0.2% EDTA, 4Na per 
litre of Hanks′ Balanced 
Salt Solution with 
phenol red 
 
CP 07.02.11 Dish 6 
 
 
50% 
 
Gibco Cell dissociation 
buffer (Invitrogen, Cat 
No: 13150-016) 
 
Enzyme-free aqueous 
formulation of salts, 
chelating agents, and 
cell-conditioning agents 
in Ca
2+
- and Mg
2+
-free 
Hanks balanced salt 
solution 
 
CP 07.02.11 Dish 9 
 
20% 
 
Trypsin-EDTA solution 
1x (Sigma, Cat No: 
59417C) 
 
0.05% porcine trypsin, 
0.02% EDTA, 4Na per 
litre of Hanks’ 
Balanced Salt Solution 
with phenol red 
 
CP 07.02.11 Dish 12 
 
<1% 
Table 4.1 Comparison of reagents used for the dissociation of primary cells for the purposes 
of passaging them. Cells were cultured in T75 flasks, and passaged by incubating three 
minutes with 3 mL of the respective cell dissociation reagent.  Cell viability was recorded 24 
h later following examination of the cells using light microscopy. 
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4.1.4 Optimisation relating to Immunofluorescence (IF) staining 
 
During initial IF experiments, analysis of data was sometimes inhibited because cells were 
absent from the coverslips when examined under the fluorescent microscope.  Hence, with 
subsequent experiments, cells were visualised under the light microscope after each step of 
the procedure.  This was to elicit at which point the cells were detaching from the coverslip.   
It became clear that the cells were being dislodged after the addition of formalin to the wells.  
This is likely due to the fact that formalin is quite a dense fluid compared to the other 
reagents utilised in this procedure.  Hence, from here on the formalin was pipetted very 
gently against the wall of the well, and care was taken to avoid direct pipetting onto the cells 
at each step of the procedure.  
This scenario more commonly occurred when cells had only been plated 24 h previous to the 
experiment, and thus had yet to adhere securely to the glass.  This problem is somewhat 
expected because the glass has a smooth, flat surface compared with that of a cell culture 
plate, which is treated  to optimise the ability of cells to adhere.   
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4.2 Description of patients and specimens 
 
4.2.1 Description of patients from whom primary cells were successfully cultured 
 
Primary pancreatic cells were successfully cultured from the resected tissue of 10 patients at 
the RLUH.  Table 4.2 lists the age and gender of these patients, along with the date of their 
resection, their clinical diagnosis, and the histopathological details of the excised tissue 
sample. 
Attempts were made to culture cells from more than 10 patients but several problems were 
encountered during sample collection.  For example, the Pathology Department at the Royal 
Liverpool University Hospital (RLUH) closes at 5pm in the evening.  Occasionally an 
operation would extend past 5pm, and the specimen would be resected after this time.  As a 
result, tissue was not dissected and no samples were available to culture.  At the RLUH one 
cannot request a surgeon to excise tissue for research purposes, in case this action interferes 
with diagnosis and staging later undertaken by the pathologist.   
In other cases, the pathologist having examined the specimen, confirmed that the tumour was 
very small and that the whole sample was required for diagnostic and staging purposes.  
Furthermore, preoperative investigations such as CT scans were sometimes misleading.  They 
occasionally indicated the presence of a pancreatic tumour before the resection, which was 
then found to be absent during histopathological examination. 
74 
 
Date of 
sample 
collection 
Age / 
Gender 
Clinical diagnosis 
/ tumour stage 
 
 
Histopathology details 
19.10.10 
 
 
 
75 / F PDAC in head of 
pancreas 
pT3 pN1 M0 pR0 
 
Poorly differentiated tumour measuring 31 x 20 x 19 mm.  Perineural invasion present but no vascular invasion.  
No involvement of anterior, medial or posterior margins of pancreas, although tumour does reach duodenal 
submucosa.  Three lymph nodes resected from posterior superior location contain metastatic carcinoma.  Other 
lymph nodes are not involved. 
07.12.10 
 
 
37 / F Mucinous cystic 
neoplasm in tail of 
pancreas 
Multiloculated cyst measuring 110 x 110 x 25mm.  Cyst lining is smooth and shiny, and cyst content is mucoid 
and watery.  Focal solid area present which represents around 5% of total volume.  No high-grade dysplasia or 
stromal invasion, even in the solid areas.  Background pancreas shows features of Chronic Pancreatitis. 
13.12.10 
 
 
 
45 / F PDAC in head of 
pancreas 
T3 N1 M0 R1 
 
Ill-defined solid grey-white lesion, up to 27mm in its maximum dimension.  Tumour is poorly differentiated and 
invades into the ampulla and peripancreatic fat.  There is florid perineural and vascular invasion.  Necrosis is 
present within tumour.  Ten of 19 lymph nodes resected contain metastatic carcinoma.  Background pancreas 
shows features of Chronic Pancreatitis.  Focal areas of squamous metaplasia and PanIN-3 present.   
14.12.10 
 
 
 
51 / F Cholangiocarcino-
ma 
pT3 pN1 M0 pR0 
 
 
White lesion measuring 20 x 15 x 15mm.  Moderately differentiated tumour arising from the intrapancreatic bile 
duct in the head of pancreas, and extensively involves the adjacent pancreas.  Two of 29 resected lymph nodes 
have metastatic carcinoma.  Three other lymph nodes show a granulomatous inflammatory response.  Foci of 
perineural invasion but no vascular invasion.  Pancreatic resection margin and medial margin are involved by 
carcinoma.    
20.12.10 
 
 
 
74 / F Adenosquamous 
PDAC in head of 
pancreas 
T3 N1 M0 R0 
Solid grey/white tumour, 35mm in its maximum dimension.  Background pancreas appears fibrotic with multi-
focal PanIN-2 and -3.  It is a poorly differentiated tumour which has locally invaded into peripancreatic fat, 
ampulla, duodenal wall, and the intra-pancreatic bile duct.  Florid perineural invasion and vascular invasion seen.  
There is necrosis within the tumour.  One of the 32 lymph nodes resected contains metastatic adenocarcinoma.  
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19.01.11 
 
 
71 / M PDAC in head of 
pancreas 
pT3 pN0 M0 pR1 
Firm, white tumour measuring 50 x 45 x 25mm.  It is a moderately, and focally poorly differentiated tumour.  
There is focal invasion of the muscularis propria of the duodenum, extensive perineural and intramural invasion 
as well, but no vascular invasion.  Twelve lymph nodes contain reactive changes only.   
25.01.11 
 
 
 
52 / M Chronic alcoholic 
pancreatitis.  No 
clinical suspicion 
of malignancy 
There is florid peri-tubular and intralobular fibrosis, loss of acinar tissue, mild chronic inflammation, islet cell 
hyperplasia, and neutrophil polymorphs within dilated ducts and ductules.  There is PanIN-1A but no dysplasia or 
malignancy.  Twelve lymph nodes have reactive changes only. 
28.01.11 
 
 
 
61 / F PDAC in head of 
pancreas 
pT3 pN0 M0 pR0 
 
White tumour with dimensions of 30 x 20 x 20mm.  It is well/moderately differentiated and there is no vascular 
invasion, but extensive perineural invasion is present.  Carcinoma extends to the duodenal wall.  Foci of PanIN1b 
also present.  Chronic Pancreatitis is present elsewhere in the pancreas, including in the excision margins.  
Twenty-seven lymph nodes show no evidence of metastatic carcinoma.   
07.02.11 
 
 
 
36 / F Hereditary 
pancreatitis. 
No clinical 
suspicion of 
malignancy 
There is extensive fibrosis and calcification with dilated pancreatic duct measuring up to 10mm in diameter and 
dilated branch ducts.  Also, there is marked lobular atrophy with most lobules showing only residual ductules and 
scanty remaining acinar tissue.  Large ducts are dilated, disrupted, and show squamous metaplasia.  There are 
abundant foci of PanINs-1A & 1B, and a single focus of PanIN-2.  There is no evidence of malignancy.  Twenty 
lymph nodes resected show reactive changes only. 
10.02.11 
 
68 / F Ampullary 
carcinoma 
pT4 pN1 M0 R0 
Ulcerated tumour measuring 20 x 15 x 20mm.  Poorly-differentiated and extending into adjacent pancreas, 
duodenal wall and peripancreatic fatty tissue.  Vascular and perineural invasion are present.  Two of the resected 
lymph nodes contain metastatic carcinoma. 
Table 4.2 Clinical diagnosis and histopathology details of 10 patients from whom primary cells were successfully cultured 
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4.2.2 Nomenclature for pancreatic primary cell cultures 
 
Flasks of primary pancreatic cells in culture have been named according to the resection date 
of the specimen from which they were derived, the pathology of the explanted tissue, the 
dish/well number that they were extracted from, and the number of passages which they have 
undergone in culture.   
For example, a flask of cells named ‘PDAC 19.01.11 well 2 passage 1’ would represent cells 
in their first passage having been extracted from well number 2 of a 6-well plate (or dish no. 
2), which contained explanted tissue constituting PDAC, from a patient who underwent 
resection on 19.01.11.   
It is essential to distinguish between the different dishes/wells of primary cells from the same 
patient, due to the potential heterogeneity of these cells.   
 
  
77 
 
4.2.3 Haematoxylin and Eosin (H/E) staining of resected tissue 
 
Photographs were taken of H/E stained tissue of two patients from whom cultures of primary 
cells were derived.  The photographs displayed immediately below (Figure 4.2) are those of a 
PDAC tissue sample resected 28
th
 January 2011. 
 
Figure 4.2 Photographs of H/E stained sections from a 
pancreatic cancer specimen used for the establishment of 
primary cell cultures.  A, B:  Normal pancreatic lobules 
(black arrow).  C:  Normal interlobular duct epithelium 
(black arrow). D: PanIN-1A (black arrow).  E:  
Adenocarcinoma (black arrow) surrounded by desmoplastic 
stroma (white arrow).  F:  Perineural invasion (black arrow).  
G:  Adenocarcinoma (black arrow) with adjacent Chronic 
Pancreatitis (white arrow). 
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Figure 4.3 below shows H/E stained tissue from a chronic pancreatitis sample resected 25
th
 
January 2011. 
 
Figure 4.3 Photographs of H/E stained sections from a chronic pancreatitis sample used to establish 
of primary cell cultures.  A:  Intralobular fibrosis (black arrow).  B:  Intralobular (black arrow) and 
perilobular (white arrow) fibrosis.  C:  Intralobular fibrosis (black arrow).  D:  Neuronal hyperplasia 
(black arrow).  E:  Scanty neutrophils within disrupted duct (black arrow).  F:  PanIN-1A (black 
arrow) and adjacent normal duct (white arrow) 
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4.3 Description of pancreatic primary cell morphology 
 
4.3.1 Light microscopy of primary cultured cells 
 
Phase-contrast images were taken of primary cultured cells once they had been transferred 
from the original dish/well into T25 flasks.  Cells with different morphologies were 
sometimes identified between the different flasks of cells, despite having originated from the 
same patient tissue sample.  
All of the cells observed by microscopy appeared mesenchymal in shape, with long 
cytoplasmic processes extending outwards from the cell body.  Several different cell 
morphology types were observed and are arbitrarily referred to here as types A, B and C.  
Type A, were the most commonly seen cells, which were large with a myofibroblast-like 
phenotype as pictured in Figure 4.4. 
 
Figure 4.4 Light microscopy images of cells with Type A morphology.  Left panel:  Cells 
from sample CP 25.01.11 Dish 9 passage 3 taken at 10x magnification;  Right panel:  Cells 
from sample PDAC 28.01.11 Dish 7 passage 3 taken at 40x magnification. 
 
Type B cells, as displayed in Figures 4.5 and 4.6 were less commonly observed.  These were 
similar shaped cells but smaller in size, and possessing thinner cellular processes.  Their 
shape seemed to differ according to the length of time they had adhered to the cell culture 
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plate.  Having only adhered to the plate 48 h previously the cells appear compact as shown in 
Figure 4.5. 
 
 
Figure 4.5 Light microscopy images of cells with Type B morphology.  PDAC 28.01.11 Dish 
4 passage 2.  Left panel:  10x magnification; Middle panel:  20x magnification; Right panel:  
40x magnification. 
 
However, after another 3d in culture the cell shape developed with the cellular processes 
extending into the surrounding environment as shown in Figure 4.6 below.     
 
Figure 4.6 Light microscopy images of cells with Type B morphology.  Left panel:  Cells 
from sample  PDAC 28.01.11 Dish 4 passage 2 taken at 10x magnification; Right panel:  
Cells from sample PDAC 28.01.11 Dish 4 passage 2 taken at 20x magnification. 
 
Finally, there appeared to be a third cell type, referred to as type C which were characterised 
by an even more slender morphology, with longer and thinner cellular processes to the 
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aforementioned cells.  However, these cells were much more rarely encountered, and were 
only discovered in three of the wells/dishes cultured with explanted tissue from the various 
samples.  These cells were propagated into T25 flasks and were pictured as displayed in 
Figure 4.7. 
 
Figure 4.7 Light microscopy images of cells with Type C morphology.  CP 25.01.11 Dish 14 
passage 3 cells.  Left panel:  10x magnification; Right panel:  20x magnification. 
 
Hence, several different types of primary cell seem to have grown out of the explanted tissue.  
The majority of the primary cells were of the phenotype illustrated in Figure: 4.4.   
These cells could not be characterised from morphology alone, thus immunofluorescence 
staining/microscopy was used in an attempt to differentiate between the various cell 
populations, and to elicit the expression of stellate cell markers.   
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4.4 Immunofluorescence characterisation of primary cultured cells 
 
In a series of experiments, the expression of the four stellate cell markers were quantified, 
namely alpha SMA, GFAP, desmin and vimentin (See Section 1.3.2).  This expression was 
measured in the various types of primary cultured cell, the immortalised pancreatic stellate 
cell line (RLT-PSC) and the numerous cancer cell lines. 
 
4.4.1 Evaluation of alpha SMA and GFAP expression 
 
Initial attempts at characterisation of primary cultured cells were performed on cells derived 
from the explanted pancreatic tissue of a patient who underwent resection for PDAC on 18
th
 
October 2010.  The RLT-PSCs and the pancreatic cancer cell line, MiaPaCa-2 were also 
stained to act as positive and negative cell controls respectively. 
Prior to fixation with formalin, the primary cells having been cultured on glass coverslips for 
48 h, appeared like the cells displayed in Section 4.3.1 Figure 4.4 i.e. they displayed ‘type A’ 
morphology. 
All cells were blocked in a PBS-based solution containing 2% BSA and antibodies were 
diluted in a PBS-solution containing 1% BSA (see Materials and Methods section 3.6.1).  
The primary antibodies used to stain the cells were rabbit polyclonal GFAP and mouse 
monoclonal αSMA antibody (Abcam).  Each of the cell types were also stained with an 
isotype control antibody.  The secondary antibodies utilised were cy3 anti-rabbit (red) and 
FITC anti-mouse (green) both diluted to 1:100.     
 
Isotype 
As shown in Figure 4.8 below, both rabbit and mouse isotype control antibodies displayed 
negative binding in both the primary cell sample and the Mia-PaCa-2 cells.  Therefore, 
subsequent staining in this experiment is considered to be specific to the antibody of interest.   
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Figure 4.8 Immunofluorescence images. A:  PDAC 18.10.10 well 3 passage 2 stained with 
isotype mouse 1:500.  B:  MiaPaCa-2 cells stained with isotype mouse 1:500.  C:  PDAC 
18.10.10 well 3 passage 2 stained with isotype rabbit 1:500.  D:  MiaPaCa-2 stained with 
isotype rabbit 1:500.  All images taken at 100x magnification.  
Alpha SMA 
Figure 4.9A displays a primary cell with distinctive alpha SMA staining (green) at a dilution 
of 1:500, although Figure 4.9B illustrates that while a proportion of these cells expressed 
alpha SMA, some also lacked expression.  However, the primary cells did not express alpha 
SMA when the antibody was diluted to 1:1000 (Figure 5.0 left panel).  MiaPaca-2 cells 
(Figure 4.9C, and Figure 5.0 right panel) and RLT-PSC cells (Figure 4.9D) did not express 
alpha SMA at either dilution. 
GFAP 
GFAP expression (red) was positive in all cells when the antibody was utilised at a dilution of 
1:500 (Figure 4.9), but was absent at an antibody dilution of 1:1000 (Figure 5.0).  Staining 
was even positive in the MiaPaCa-2 cells which were a negative cell control (Figure 4.9C).   
A 
D 
B 
C 
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Figure 4.9 Immunofluorescence images.  Cells double-stained with GFAP (red) & αSMA 
(green) 1:500.  A & B:  PDAC 18.10.10 well 3 passage 2.  C:  MiaPaCa-2.  D:  RLT-PSC.  
All images taken at 100x magnification. 
 
 
Figure 5.0 Immunofluorescence images.  Cells double-stained with GFAP (red) & αSMA 
(green) 1:1000.  Left panel:  PDAC 18.10.10 well 3 passage 2.  Right panel:  MiaPaCa-2.  All 
images taken at 100x magnification. 
A B 
D C 
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4.4.2 Evaluation of Desmin and Vimentin expression 
 
Two cell samples, both derived from the explanted pancreatic tissue of a patient who 
underwent resection for an adenosquamous variant of PDAC on 20
th
 December 2010, were 
evaluated for the expression of desmin and vimentin.  Unfortunately, the primary cells used 
in the previous section had not yet reached full confluency at the time of performing this 
experiment.  Hence, a different sample of primary cells had to be utilised.  Once again, both 
of these samples displayed a ‘type A’ morphology as described in Section 4.3.1.     
The expression of desmin and vimentin was evaluated using a rabbit polyclonal desmin 
antibody (Abcam) and a goat polyclonal vimentin antibody (Santa Cruz) respectively as 
described in the Materials and Methods Section 3.6.1.  Cells were blocked with the same 
method as in Section 4.4.1.  The desmin antibody was applied in serial dilutions to find the 
optimal concentration for use in IF staining.  Only one dilution (1:50) was used for vimentin 
due to the low numbers of primary cells available for staining.    
The concentrations of both secondary antibodies were reduced to a 1:400 dilution in this 
experiment, compared to 1:100 in the previous experiment.  This was a precaution taken to 
prevent non specific binding and to stop the MiaPaCa-2 cancer cells from staining positively 
again (please see Section 4.4.1), cells which were supposed to be acting as a negative control.  
Furthermore, the green fluorescent tag, FITC was exchanged for an Alexa Fluor-488 
antibody.  The fluorescence of the latter is reported to last much longer than that of the 
former i.e. months as opposed to days.  The red cy3 anti-mouse antibody was continued.  
Figure 5.1 below displays the findings from this experiment.   
Isotype 
As displayed in the top row of Figure 5.1, the isotype control antibody exhibited an intense 
fluorescence in all three cell samples, and this was even brighter than the green stain elicited 
when the same cells were stained with desmin.  Hence, any green stain associated with the 
desmin antibody is invalid, and should be considered to be non-specific binding.  Vimentin 
expression was positive and equal in intensity between all cells.  However, no goat isotype 
control antibody was utilised, and thus non-specific binding cannot be ruled out for the red 
stain. 
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Figure 5.1 Immunofluorescence images.  Left panel: PDAC 20.12.10 Dish 5 passage 2.  
Middle panel:  PDAC 20.12.10 Dish 7 passage 2.  Right panel:  MiaPaCa-2. Cells were 
stained with isotype rabbit 1:50, desmin (rabbit) at serial dilutions 1:50, 1:100, 1:200, and 
vimentin (goat) 1:50.  DAPI stain (blue) represents cell nuclei. 
 
 
PDAC 20.12.10 D5 P2 PDAC 20.12.10 D7 P2 MiaPaCa-2 
Isotype 
rabbit 
(green) 
1:50  
 
Desmin 
(green) 
1:50  
 
Desmin 
(green) 
1:100  
 
Desmin 
(green) 
1:200  
 
Vimentin 
(red) 
1:50  
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4.4.3 Further evaluation of Desmin, GFAP and alpha SMA expression  
 
Mouse monoclonal desmin and rabbit polyclonal GFAP antibodies were purchased from 
DAKO and were used to stain another set of primary cultured cells.  These results would be 
compared with the previous stains that were undertaken with the antibodies purchased from 
Abcam, to deduce whether the antibodies from Abcam were binding non-specifically to cells 
(See Sections 4.4.1 and 4.4.2).  In addition, expression of alpha SMA was measured, and 
some cells were incubated with the secondary antibody alone to elicit whether secondary 
antibodies were binding non-specifically.  
Instead of using BSA for blocking as in Sections 4.4.1 and 4.4.2, a PBS based solution 
containing 10% goat serum was used both for blocking cells and dilution of antibodies (See 
Materials and Methods section 3.6.1).  This alternative method of blocking may have been 
better at preventing non-specific binding if any was taking place.  Cells were double stained 
with serial dilutions of all three primary antibodies.  AlexaFluor-488 anti-rabbit and cy3 anti-
mouse antibodies were used as secondary tags and were both diluted to 1:1000, a higher 
dilution than in the two previous experiments (See Sections 4.4.1 and 4.4.2).  The higher 
dilution of secondary was used to elucidate whether the cancer cell lines were previously 
staining positively for stellate cell markers non-specifically because of too high a 
concentration of secondary antibody. 
For the first time, primary cells with different morphologies were stained alongside one 
another.  These included PDAC 20.12.10 dish 5 passage 4 cells (type A morphology) and CP 
25.1.11 dish 8 passage 2 cells (type B morphology).  The aim was to see whether any 
difference in marker expression could be elicited between the cells types.  If such differences 
were present this could indicate two distinct cell types.  RLT-PSCs and Panc-1 cancer cells 
were utilised as positive and negative control cells respectively.  
Figure 5.2 displays the results when the four different cell types were double-stained with 
isotype controls, and serial dilutions of GFAP, desmin and alpha SMA.   
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Figure 5.2 
Immunofluorescence 
images.   PDAC 
20.12.10 Dish 5 passage 
4, CP 25.01.11 Dish 8 
passage 2, RLT-PSC, 
Panc-1 stained with 
rabbit and mouse isotype 
(1:200), and serial 
dilutions of GFAP 
(rabbit), Desmin 
(mouse), and αSMA 
(mouse).   
 
Rabbit (green) 
and mouse 
(red) isotype 
1:200 
 
GFAP (green) 
1:200.  Desmin 
(red) 1:200  
 
GFAP (green) 
1:500.  Desmin 
(red) 1:500  
 
GFAP (green) 
1:750.  αSMA 
(red) 1:500  
 
GFAP (green) 
1:1000.  αSMA 
(red) 1:1000  
 
PDAC 20.12.10 Dish 
5 passage 4 (Type A)  
 
CP 25.01.11 Dish 8 
passage 2 (Type B)  
 
RLT-PSC Panc-1  
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Isotype 
The rabbit isotype control antibody stained weakly for all cell types, unlike the bright green 
stain displayed in the previous experiment (See Section 4.4.2).  This is probably related to the 
increased dilution of the isotype control (1:200) in this experiment, compared to 1:50 in the 
previous experiment.  Mouse isotype antibody expression was negative in all the cell types, 
apart from the Panc-1 cells in which there was very faint red fluorescence.     
 
GFAP 
As shown in Figure 5.2, the PDAC 20.12.10 Dish 5 passage 4 cells (Type A morphology) 
stained more brightly green against GFAP than with the rabbit isotype control, especially 
when GFAP was used at dilutions of 1:200 and 1:500.   Hence, the green fluorescence 
emitted by these cells is considered to be specific for GFAP, and non-specific binding can be 
ruled out.   
Unfortunately, Panc-1 cells also fluoresced bright green with the GFAP marker despite using 
a new antibody from DAKO, and also despite the drop in concentration of secondary 
antibody to 1:1000 from 1:400 in the previous experiment.  Therefore, an alternative cancer 
cell line to Panc-1 and MiaPaCa-2 will be used in the subsequent investigations.    
CP 25.01.11 dish 8 passage 2 (Type B morphology) cells expressed GFAP very faintly, and 
this was clearly much weaker than the green fluorescence emitted by the PDAC 20.12.10 
Dish 5 passage 4 cells.  The RLT-PSC cells displayed some green fluorescence when stained 
with GFAP, although this was comparable in intensity to the green fluorescence emitted for 
the rabbit isotype stain and hence could be non-specific.  For all four cell types, the optimal 
dilution for GFAP appeared to exist somewhere between 1:200 and 1:500, and so subsequent 
experiments will utilise dilutions of GFAP within this range.   
 
Desmin 
The new desmin antibody from DAKO was utilised.  Most of the cell samples did not express 
desmin (Figure 5.2).  The RLT-PSCs did produce some weak patchy staining when the 
desmin antibody was applied at a dilution of 1:200, although this was not very convincing.  
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Alpha SMA 
Alpha SMA expression was observed in both primary cultured cell samples.  However, the  
fluorescent red stain was higher in intensity for the PDAC 20.12.10 dish 5 passage 4 (Type A 
morphology) cells compared to the CP 25.01.11 Dish 8 passage 2 (Type B morphology) cells.  
A dilution of 1:1000 for the alpha SMA antibody was too high, whereas 1:500 seemed to 
work well.  It is yet unknown whether this is the optimal dilution, so the antibody will be 
trialled in subsequent experiments at lower dilutions.  The RLT-PSC cells and Panc-1 cells 
did not express alpha SMA at either of the two antibody dilutions.   
In a similar scenario to that of Section 4.4.1, there were variations in the expression of alpha 
SMA between primary cells originating from the same sample.  Approximately 20% of the 
PDAC 20.12.10 Dish 5 passage 3 (Type A) cells expressed this marker.  However, under 5% 
of the CP 25.01.11 Dish 8 passage 2 (Type B) cells stained positively.  These approximations 
were determined by calculating the proportion of cells that stained positively in 40 different 
fields of view on the microscope at 100x magnification.  A total of 71 PDAC 20.12.10 dish 5 
passage 4 cells were counted, of which 14 stained positive for alpha SMA (19.7%).  A total 
of 129 CP 25.01.11 dish 8 passage 2 cells were counted of which only 3 showed expression 
of alpha SMA (2.3%). 
 
Secondary antibody only 
The images in Figure 5.3 were taken from cells double-stained with secondary antibody 
alone.  Very faint red staining was observed in all of the cells indicating that the cy3 anti-
mouse antibody displays some non-specific binding.  However, this red expression was very 
weak and thus not significant enough to warrant the use of different secondary antibody in 
subsequent experiments.  The green fluorescence of the AlexaFluor-488 anti-rabbit antibody 
was absent as expected. 
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Figure 5.3 Immunofluorescence images.  Secondary antibody stain only:  Alexa Fluor-480 
anti-rabbit (green), Cy3 anti-mouse (red) both 1:1000.  A:  PDAC 20.12.10 Dish 5 passage 4.  
B:  CP 25.01.11 Dish 8 passage 2.  C:  RLT-PSC.  D:  Panc-1 
A 
D 
B 
C 
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4.4.4 Further evaluation of desmin and alpha SMA expression 
 
It has already been established that the Type A morphology cells express alpha SMA and 
GFAP (See Sections 4.4.1, and 4.4.3).  Ideally the results for GFAP expression need to be 
supported by negative control cell data.   
In this experiment, two more samples of primary cells (Type A morphology) were 
characterised for desmin expression using the new antibody from DAKO.  This antibody has 
been previously applied at dilutions of 1:200 and 1:500 but no fluorescence was emitted by 
any of the cells (See Section 4.4.3).  In the following experiment the desmin antibody was 
utilised at a dilution of 1:50.  RLT-PSCs were not utilised as a positive control cell 
considering their lack of expression of stellate cell markers in previous experiments.  Thus 
far, MiaPaCa-2 and Panc-1 cells have expressed mesenchymal and stellate cell markers (See 
Sections 4.4.1 to 4.4.3).  Hence, an alternative cancer cell line, the BXPC3 cell line, was 
trialled as a negative control cell in the following experiment.  As yet no negative control cell 
has been found.  
A PBS based solution containing 10% goat serum was used to block cells and a solution 
containing 2% goat serum was employed for antibody dilution.  The green staining was 
elicited by Alexa Fluor-488 anti-rabbit and anti-mouse, and the red staining by cy3 anti-goat 
all diluted to 1:500.   
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Figure 5.4 Immunofluorescence images.  Primary cultured cells with ‘type A’ morphology 
characterised for alpha SMA and desmin expression.  Left panel:  PDAC 13.12.10 well 9 
passage 2.  Middle panel:  CP 07.02.11 Dish 7 passage 2.  Right panel:  BXPC3 
 
As expected, alpha SMA expression was positive in both samples of primary cells (Type A), 
and more than 90% of the cells expressed this protein.  BXPC3 cells however did not exhibit 
alpha SMA.  The mouse isotype stains were negative in the primary cells, and desmin 
expression was positive but very faint.  Hence, these primary cells could possibly express a 
low level of desmin although the data is not very convincing due to the very faint stains.  The 
positive fluorescence for desmin in the BXPC3 cells is invalid considering that the mouse 
isotype stained even brighter. 
 
 
 
PDAC 13.12.10 well 
9 passage 2 (Type A) 
 
CP 07.02.11 Dish 7 
passage 2 (Type A) 
 
BXPC3 
 
Isotype 
mouse 
(green) 
1:200  
 
Desmin 
(green) 
1:50 
(mouse)  
 
Alpha 
SMA 
(green) 
1:100 
(mouse)  
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4.4.5 Comparison of marker expression between different morphology types 
 
PDAC 28.01.11 dish 4 passage 3 (type B) cells and PDAC 19.01.11 dish 12 passage 3 (type 
C) cells were  stained with alpha SMA, GFAP and desmin antibodies.  RLT-PSC and Suit-2 
cancer cells were also stained.  The latter were trialled as a potential negative cell control.   
For this experiment the concentration of mouse monoclonal alpha SMA was increased to 
1:300, from a concentration of 1:500 that was used previously in Section 4.4.3.  The increase 
in antibody concentration was to elucidate whether a greater proportion of cells would stain 
positively for alpha SMA at this higher concentration.  Rabbit polyclonal desmin (Abcam) 
was utilised at 1:100, and rabbit polyclonal GFAP (DAKO) at 1:400.  As mentioned in 
Section 4.4.3 the optimal dilution for GFAP (DAKO) seemed to exist somewhere between 
1:200 and 1:500, thus 1:400 was the chosen dilution on this occasion.    
All primary antibodies were incubated overnight at 4°C.  Cy3 anti mouse, alexa fluor-488 
anti rabbit and alexa fluor-488 anti mouse antibody were utilised at 1:500.  Prior experiments 
demonstrated that an increased dilution of the secondary antibody to 1:1000 had no effect on 
non-specific binding (See Section 4.4.3).  All cells were blocked in a PBS based solution 
containing 10% goat serum, and antibodies were diluted in a solution containing 2% goat 
serum (see Materials and Methods section 3.6.1).   
The results of these experiments are illustrated in Figure 5.5. 
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Figure 5.5 
Immunofluorescence 
images.  3 different 
cell morphology types 
stained with rabbit 
isotype control, 
GFAP (rabbit), 
αSMA (mouse), 
desmin/Abcam 
(rabbit) 
 
PDAC 28.01.11 
dish 4 passage 3 
(Type B)  
 
PDAC 19.01.11 
dish 12 passage 3 
(Type C)  
 
RLT-PSC 
 
Suit-2 
 
Isotype 
rabbit 
(green) 
1:400  
 
GFAP 
(green) 1:400 
α SMA (red) 
1:300  
 
Desmin 
Abcam 
(green) 
1:100  
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Isotype, GFAP, desmin 
The rabbit isotype antibody (1:400) produced positive fluorescence in all four cell types, 
similar to the scenario in Section 4.4.2.  For the majority of the cells, the fluorescence 
associated with the isotype control was exhibited at an equal or a higher intensity to the 
fluorescence produced by the other antibodies (GFAP, and desmin from Abcam).  Hence, the 
results for GFAP and desmin expression are considered invalid, and the green fluorescence is 
considered to be a result of non-specific binding.  The only exception to this was the RLT-
PSC cells which stained for GFAP at a brighter intensity than that of the rabbit isotype 
control, thus providing evidence that the RLT PSC cells express this marker.  
Alpha SMA 
As was the case in a previous alpha SMA stain (see Section 4.4.3), the number of type B 
morphology cells expressing this marker was under 5%.  Interestingly, around 50% of the 
type C morphology cells expressed alpha SMA (Figure 5.5).  The same method of cell 
counting was used here as in section 4.4.3, where 40 fields of view were analysed on the 
microscope at 100x to determine the proportion of cells staining positive.  A total of 148 
PDAC 28.01.11 dish 4 passage 3 cells were counted, of which 6 stained positive for alpha 
SMA (4.1%).  A total of 124 PDAC 19.01.11 dish 12 passage 3 cells were counted, and 70 of 
these cells exhibited the alpha SMA marker (56.4%).   
The Suit-2 cells stained negatively for alpha SMA. This was also true for the RLT-PSC cells, 
despite the antibody concentration being increased from 1:500 to 1:300 compared to the last 
experiment in which they were stained (See Section 4.4.3). 
 
 
 
 
 
 
 
97 
 
4.4.6 The effect of TGFβ treatment on alpha SMA expression 
 
The proportion of primary cells within each sample exhibiting alpha SMA has been rather 
low in previous sections.  Hence, TGFβ was applied to both ‘type A’ and ‘type B’ 
morphology cell types (See Section 3.7.1) to determine whether the number of cells 
expressing this protein would increase.  The reason for this being that TGFβ has been shown 
in the literature to stimulate inactivated fibroblasts, myofibroblasts and stellate cells into 
alpha SMA expressing cells in vitro 
49;82;126;127
.   
The two primary cell samples utilised in this experiment were PDAC 28.01.11 dish 7 passage 
4 cells (type A) and PDAC 28.01.11 dish 4 passage 5 cells (type B).  RLT-PSC and cancer 
cells were not included in the experiment because both fail to express the alpha SMA marker.   
A PBS based solution containing 10% goat serum was used to block cells and a solution 
containing 2% goat serum was used to dilute antibodies.  Isotype mouse was used at a 
dilution of 1:300 and alpha SMA at serial dilutions of 1:200 and 1:400.  Alexa Fluor-488 anti 
mouse, which represented the secondary antibody was diluted 1:500.   
As shown in Figure 5.6 (below), there was no positive staining to the mouse isotype control 
in either of the primary cultured cells.  Surprisingly, the majority of the type A morphology 
cells expressed alpha SMA at both dilutions, with or without TGFβ treatment.  Expectedly, 
very few type B cells expressed alpha SMA at either dilution.  However, over 90% of the 
cells that were exposed to TGFβ displayed expression of alpha SMA afterwards.  This 
increase in number of cells expressing alpha SMA was observed at both dilutions.  PDAC 
28.01.11 dish 4 passage 5 cells that were stained with alpha SMA (1:200) were counted as 
described in section 4.4.4.  Of the cells treated with TGFβ, a total of 113 cells were counted 
from 40 different fields of view. Of these, 105 expressed the characteristic strand-like 
staining of alpha SMA (93%).  However, alpha SMA was expressed by very few cells in the 
untreated cells stained at the same dilution (1:200).  From a total of 96 cells, only 2 of these 
displayed green staining (2%). 
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Figure 5.6 Immunofluorescence images.  Alpha SMA 
stain (green) for Type A and Type B morphology cells 
with or without prior TGFβ stimulation 
PDAC 28.01.11 dish 
7 passage 4 (Type A)  
 
PDAC 28.01.11 dish 4 
passage 5 (Type B)  
 Isotype 
mouse  
1:300  
 
αSMA 
1:400  
 
αSMA 
1:400 
with 
TGFβ  
 
αSMA 
1:200  
 
αSMA 
1:200 
with 
TGFβ  
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4.4.7 Evaluation of Cytokeratin expression 
 
Pancreatic stellate cells are expected to have absent or low expression of cytokeratin, an 
epithelial cell marker.  Mouse monoclonal pan-cytokeratin antibody was used to stain PDAC 
28.01.11 dish 4 passage 7 (Type B) cells and CP 25.01.11 dish 14 passage 4 (type C) cells in 
order to determine whether these cultures were contaminated with epithelial cells.  BXPC3 
cancer cells were chosen to represent a positive cell control for cytokeratin expression.     
Cells were blocked in a PBS based solution containing 10% goat serum, and antibodies 
incubated in a PBS based solution containing 2% goat serum.  The pan-cytokeratin antibody 
was used at dilutions of 1:100 and 1:300.  AlexaFluor-488 anti-mouse antibody was the 
chosen secondary antibody and was diluted to 1:500. 
 
 
 
Figure 5.7 Immunofluorescence images.  Primary cultured cells and BXPC3 epithelial cancer 
cells stained with cytokeratin antibody (green).  
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Figure 5.7 illustrates that isotype stains (1:200) of the primary cells were negative or very 
weak.  Cytokeratin staining in the primary cells was either absent or very weak at 1:300 and 
slightly more intense at 1:100.  The BXPC3 cells displayed positive cytokeratin expression, 
which was very intense at the 1:100 dilution.  However, the mouse isotype control was also 
positive in the BXPC3 cells, albeit at a lower intensity in comparison with the fluorescence 
elicited by the cytokeratin antibody.  Hence, one can conclude that the BXPC3 cells display 
positive cytokeratin expression whereas the primary cells do not.   
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4.5 MicroRNA analysis 
 
Along with RLT-PSC cells, two samples of primary cultured cells were taken forward for use 
in miRNA quantification experiments.  These were PDAC 28.01.11 dish 7 passage 5 and CP 
07.02.11 dish 7 passage 2 cells, both of which possessed the Type A morphology (See 
Section 4.3.1).  From here on these cells will be referred to as ‘PDAC’ and ‘CP’ respectively. 
The symbols ‘+’ and ‘-‘ are used to demonstrate whether or not the cells were pre-treated 
with TGFβ.  As mentioned earlier, cells with the type A morphology may possibly comprise 
pancreatic stellate cells in view of their positive expression of alpha SMA and GFAP in 
previous experiments (See Section 4.4).     
 
 
4.5.1 RNA purification from primary cultured cells and RLT-PSCs 
 
A nanodrop spectrophotometer was used to quantify the RNA purified from cultured cells 
(Table 4.3) using the miRNeasy kit from Qiagen (See Section 3.7).  The technique used to 
extract miRNA is also described in this section.   
 
Sample Reading 1 (ng/µl) Reading 2 (ng/µl) Average reading (ng/µl) 
PDAC + 1.5 2.5 2 
PDAC - 4.0 4.5 4.25 
CP + 21.8 21.8 21.8 
CP - 7.5 8.7 8.1 
RLT-PSC+ 50.0 47.3 48.65 
RLT-PSC- 47.0 49.6 48.3 
Table 4.3 Total RNA quantification in primary cultured cells and RLT-PSC samples 
 
 
 
102 
 
4.5.2 Reverse transcription 
 
Reverse transcription was conducted on the RNA samples purified in the previous section.  
Table 4.4 displays the concentrations of cDNA that were yielded during this procedure.  
These were quantified using a nanodrop spectrophotometer as described in the materials and 
methods section 3.7.3. 
 
Sample cDNA content (ng/µl) 
PDAC + 916.2 
PDAC - 1469.6 
CP + 1139.8 
CP - 1456.7 
RLT-PSC+ 873.8 
RLT-PSC- 879.1 
Table 4.4 Quantification of cDNA in primary cultured cells and RLT-PSC samples 
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4.5.3 Real–time PCR quantification of the miRNA-29 family 
 
4.5.3.1 Loading concentrations of sample cDNA 
 
The miScript PCR kit from Qiagen (see Material and Methods section 3.7.4) recommend a 
loading amount cDNA approximately 1-3ng in a volume of less than 5µl.  Hence, samples of 
cDNA created by reverse transcription were too concentrated (Table 4.4) and were diluted 1 
in 1000 in RNase free water.  These were then quantified one more time using the nanodrop 
spectrophotometer (Table 4.5). 
 
Sample cDNA reading 1 
(ng/µl) 
cDNA reading 2 
(ng/µl) 
cDNA reading 3 
(ng/µl) 
cDNA average 
reading (ng/µl) 
PDAC + 7.3 7.6 8.2 7.7 
PDAC - 6.6 6.1 6.3 6.33 
CP + 6.0 5.8 6.1 6.0 
CP - 5.0 6.7 8.4 6.94 
RLT-PSC+ 6.8 7 6.8 6.87 
RLT-PSC- 5.8 5.5 6.1 5.8 
Table 4.5 cDNA quantification in primary cultured cells and RLT-PSC samples 
 
It was essential to load the amount of cDNA recommended by the kit manufacturer i.e. 1 to 3 
ng dissolved in less than 5 µl.  Therefore, samples were each diluted to provide a final 
concentration of 2 ng per 3 µl for each PCR reaction.  These dilutions were calculated on the 
basis that 2 ng per 3 µl is equivalent to 0.66 ng per 1 µl.  Therefore, the cDNA concentrations 
were divided by 0.66 to provide the necessary dilution ratio.  These are listed in Table 4.6. 
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cDNA 
sample 
Average cDNA 
reading (ng/µl) 
Dilution ratio of 
cDNA to RNase 
free water 
Volume of RNase free 
water to add to 10 µl 
of cDNA 
PDAC + 7.7 1:11.66 106.6 
PDAC - 6.33 1:9.59 85.9 
CP + 6.0 1:9 80 
CP - 6.94 1:10.5 95 
RLT-PSC+ 6.87 1:10.4 94 
RLT-PSC- 5.8 1:8.79 77.9 
Table 4.6 Volume of dilutent needed to provide 2 ng/ 3 µl of cDNA per PCR reaction 
 
The cycling conditions required for the amplification of miRNA are described in the Material 
and Methods section 3.7.4.  Real-time PCR was performed with the six samples shown in 
Table 4.6 above.  Each sample was incubated with four different primers.  The miRNA-29 
primers included a, b and c subtypes.  RNU6B was a PCR control and would act as the fourth 
primer.  It is an endogenous reference RNA and its use would allow for normalisation of 
quantities of miRNA-29a, b, and c.   
Control wells in triplicate were also included for each of the four primers.  These wells 
contained the specific primers as well as the other components of the kit (See Section 3.7.4), 
but importantly lacked any cDNA.  
 
 
  
105 
 
4.5.3.2 Relative miRNA-29 quantification 
 
MicroRNA-29a, b and c were each quantified in triplicate from the two different primary cell 
samples, PDAC 28.01.11 dish 7 passage 4, and CP 07.02.11 dish 7 passage 4. 
Of the twelve control samples that were set up without cDNA, one of these showed 
contamination with cDNA, and produced a cp (crossing point) value of more than 40 cycles. 
The Tm melting curve for all of the samples is displayed in Figure 5.8 below. 
 
 
Figure 5.8 Melting curve analysis for all samples 
 
Table 4.7 below displays the Cp values when real-time PCR was performed on the primary 
cell samples with the RNU6B control primer.  For each sample, an average Cp value of the 
triplicate readings was taken.  The net difference was then calculated between the average Cp 
value for the TGFβ treated (+) cells and that of the TGFβ untreated (-) cells for RNU6B 
control primer.  These values are also listed in Tables 4.8, 4.9, and 5.0 and were later used to 
normalise the Cp values to any variations in the loading of the cDNA. 
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Sample 
cDNA 
Cp values for 
RNU6B 
Average of 
triplicate Cp 
values 
Net difference between 
+/- samples for RNU6B 
PDAC +  31.52  
31.23 
 
 
-2.38  
PDAC + 30.9 
PDAC + 31.28 
PDAC - 32.94  
33.62 PDAC - 33.89 
PDAC - 34.03 
CP + 29.11  
29.16 
 
 
+0.76 
CP + 29.17 
CP + 29.2 
CP - 28.32  
28.4 CP - 28.55 
CP - 28.33 
RLT-PSC+  26.43  
26.42 
 
 
+0.15 
RLT-PSC +  26.33 
RLT-PSC +  26.49 
RLT-PSC –  26.28  
26.27 RLT-PSC –  26.26 
RLT-PSC –  26.27 
Table 4.7 Cp values for RNU6B control for real-time PCR performed on primary cultured 
cells and RLT-PSC samples treated +/-TGFβ 
 
Figure 5.9 displays the real-time PCR data for all of the cell samples which were incubated 
with the RNU6B control primer.  It is clear that there is variation in loading of cDNA 
between the different samples.  The least difference was observed between TGF-beta treated 
and untreated RLT-PSC cells, with a Cp difference of just 0.15 (Table 4.7). The Cp 
difference of 0.76 for TGF-beta treated and untreated stellate 2 approaches a single cycle 
difference between the detection of RNU6B amplicon. The data for ‘PDAC’ cells (Cp 
difference of 2.38) indicate a greater than two cycle difference in the detection of RNU6B. 
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Figure 5.9 PCR curve for primary cultured cells and RLT-PSC samples with RNU6B control 
primer  
 
The real-time PCR data are listed for miRNA-29a, b, and c in Tables 4.8, 4.9, and 5.0 
respectively.  The average Cp value was calculated for each primary cell sample using the 
triplicate values.  The net difference between the average Cp value for the TGFβ treated (+) 
cells and the average Cp value for the TGFβ untreated (-) cells was calculated to provide an 
overall value of the expression for the particular miRNA-29.    
Due to the variation in cDNA loading, as measured by differences in the Cp values between 
the detection of the control miRNA RNU6B in the untreated and TGF-beta treated setting for 
each cell type, the net Cp values for the RNU6B control were subtracted from the net Cp 
values for the miRNA-29 primers.  This provided an approximate estimation yielding a Cp 
value for each miRNA normalised to variations in loading according to the RNU6B control 
primer.  These calculations were performed for each of the miRNA-29 family subtypes. 
Following these estimates, little difference in the levels of miRNA-29a and c between 
untreated and TGF-beta treated cells could be deduced, with the detection of these 
prospective micro-RNAs occurring within less than a single cycle difference of each other in 
the treated and untreated scenario.  The only finding that showed promise was the apparent 
downregulation of miRNA-29b in the ‘CP +’ cells treated with TGFβ (Table 4.9). Here the 
Cp value for the TGFβ treated cells was almost one cycle higher than in the untreated cells.  
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This same micro RNA showed no difference in level in treated and untreated RLT-PSC cells, 
and unfortunately the data from ‘PDAC’ cells were inconclusive, with only a single reading 
obtained in TGF-beta treated state.     
 
 
Sample 
cDNA 
Cp values for 
miRNA-29a  
Average of 
triplicate 
Cp values 
Net difference 
between +/-
samples for 
miRNA-29a 
Net difference 
between +/- 
samples for 
RNU6B (See 
Table 3.4) 
Net difference 
between net 
miRNA-29a value 
and net RNU6B 
value 
PDAC + 34.57  
35.4 
 
 
-1.9 
 
 
-2.38  
 
 
-0.48 
PDAC + 35.34 
PDAC + 36.22 
PDAC - 36.46  
37.3 PDAC - 38.22 
PDAC - 37.17 
CP + 31.99  
32.0 
 
+1.0 
 
+0.76 
 
+0.24 CP + 32.06 
CP + 31.82 
CP - 30.87  
31.0 CP - 31.16 
CP - 31.07 
RLT-PSC+  30.84  
31.0 
 
 
-0.6 
 
 
+0.14 
 
 
-0.45 
RLT-PSC +  31.13 
RLT-PSC + 30.86 
RLT-PSC - 31.58  
31.6 RLT-PSC - 31.82 
RLT-PSC - 31.46 
Table 4.8 Cp values for miRNA-29a primer for real-time PCR performed on primary cell 
samples and RLT-PSCs treated +/-TGFβ.  
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Sample 
cDNA 
Cp values for 
miRNA-29b  
Average of 
triplicate 
Cp values 
Net difference 
between +/-
samples for 
miRNA-29b 
Net difference 
between +/- 
samples for 
RNU6B (See 
Table 3.4) 
Net difference 
between net 
miRNA-29b 
value and net 
RNU6B value 
PDAC + 36.13 36.21 -0.90 -2.38  -1.48 
PDAC + 37.4 
PDAC + 35.12 
PDAC - 37.12 37.12 
PDAC - - 
PDAC - - 
CP + 35.46 36.33 +1.74 +0.76 +0.98 
CP + 36.67 
CP + 36.86 
CP - 34.74 34.58 
CP - 35.13 
CP - 33.89 
RLT-PSC+  34.83 34.96 +0.06 +0.15 +0.09 
RLT-PSC+  34.58 
RLT-PSC +  35.49 
RLT-PSC - 34.24 34.90 
RLT-PSC -  35.36 
RLT-PSC -  35.12 
Table 4.9 Cp values for miRNA-29b primer for real-time PCR performed on primary 
cultured cell samples and RLT-PSCs treated +/-TGFβ. 
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Sample 
cDNA 
Cp values for 
miRNA-29c  
Average of 
triplicate Cp 
values 
Net difference 
between +/-
samples for 
miRNA-29c 
Net difference 
between +/- 
samples for 
RNU6B (See 
Table 3.4) 
Net difference 
between net 
miRNA-29c 
value and net 
RNU6B value 
PDAC + 35.14 35.20 -2.31 -2.39  -0.08 
PDAC + 34.86 
PDAC + 35.61 
PDAC - 40 37.51 
PDAC - 36.14 
PDAC - 36.4 
CP + 33.71 33.09 +1.02 +0.76 +0.26 
CP + 32.8 
CP + 32.78 
CP - 32.31 32.07 
CP - 32.02 
CP - 31.89 
RLT-PSC+  31.53 31.75 -0.45 +0.14 -0.30 
RLT-PSC +  31.89 
RLT-PSC +  31.85 
RLT-PSC -  32.11 32.21 
RLT-PSC -  32.32 
RLT-PSC -  32.2 
Table 5.0 Cp values for miRNA-29c primer for real-time PCR performed on primary 
cultured cell samples and RLT-PSCs treated +/-TGFβ. 
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4.6 Pancreatic primary cell cryopreservation 
 
Table 5.1 provides details for all the primary cultured cells that have been cryopreserved.  
These samples are stored in freezer 2 of the GCLP biobank.   
 
Primary cultured cell 
sample 
Box 
location 
Date 
frozen 
No of 
times 
thawed 
Morphology (Type 
A/B/C): refer to 
section 3.3 
Recommended size 
flask for thawing 
(T75/T25) 
PDAC 28.01.11 D4 P4 1 x 5 25.06.11 None B T75 
CP 25.01.11 D14 P5 1 x 1 25.06.11 None C T75 
PDAC 20.12.10 D15 P1 1 x 2 07.05.11 None B T75 
PDAC 20.12.10 D7 P4 1 x 3 25.06.11 None A T75 
PDAC 20.12.10 D5 P5 1 x 4 03.06.11 None A T75 
PDAC 20.12.10 D7 P4 1 x 6 10.05.11 None A T75 
Ampul 10.02.11 D5 P3 1 x 7 14.05.11 None A T75 
PDAC 20.12.10 D5 P3 1 x 8 27.04.11 None A T25 
PDAC 20.12.10 D7 P4 2 x 1 07.05.11 None A T25 
CP 25.01.11 D3 P2 2 x 2 07.05.11 None B T75 
PDAC 20.12.10 D7 P5 2 x 4 03.06.11 None A T75 
CP 07.02.11 D20 P2 2 x 6 10.05.11 None A T25 
PDAC 28.01.11 D4 P4 2 x 5 03.06.11 None B  T75 
CP 25.01.11 D8 P4 2 x 7 10.05.11 None A  T75 
CP 25.01.11 D8 P3 2 x 8 27.04.11 None B T75 
PDAC 28.01.11 D4 P4 3 x 1 25.06.11 None B T75 
Ampul 10.02.11 D5 P2 3 x 2 07.05.11 None B T75 
CP 07.02.11 D6 P2 3 x 3 07.05.11 None A T75 
PDAC 20.12.10 D7 P5 3 x 4 03.06.11 None A  T75 
CP 07.02.11 D11 P3 3 x 5 10.05.11 None A T75 
CP 07.02.11 D14 P2 3 x 6 10.05.11 None A T75 
Ampul 10.02.11 D5 P3 3 x 7 14.05.11 None A T75 
PDAC 28.01.11 D4 P7 4 x 1 25.06.11 None B T75 
CP 25.01.11 D14 P3 4 x 2 07.05.11 None C T75 
PDAC 20.12.10 D5 P6 4 x 3 03.06.11 None A T75 
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CP 25.01.11 D7 P3 4 x 4 07.05.11 None A T75 
CP 07.02.11 D3 P2 4 x 6 10.05.11 None A T75 
PDAC 28.01.11 D10 P2 4 x 7 14.05.11 None A T75 
PDAC 28.01.11 D14 P2 5 x 1 22.06.11 None B T75 
CP 25.01.11 D9 P3 5 x 3 03.06.11 None A T75 
CP 25.01.11 D7 P3 5 x 4 07.05.11 None A T75 
PDAC 20.12.10 D5 P4 5 x 5 07.05.11 None A T25 
CP 07.02.11 D5 P2 5 x 7 10.05.11 None A T25 
CP 25.01.11 D14 P5 6 x 1 25.06.11 None C T75 
CP 25.01.11 D14 P3 6 x 2 07.05.11 None C T75 
CP 25.01.11 D3 P6 6 x 3 25.06.11 None B T75 
PDAC 18.10.10 D3 P5 6 x 4 07.05.11 None A T75 
PDAC 13.12.10 D11 P2 6 x 5 10.05.11 None A T25 
PDAC 20.12.10 D8 P1 6 x 6 10.05.11 None A T75 
PDAC 28.01.11 D4 P3 6 x 7 27.05.11 None B T75 
PDAC 20.12.10 D5 P7 7 x 1 22.06.11 None A T75 
PDAC 19.01.11 D12 P3 7 x 2 07.05.11 None B T75 
PDAC 28.01.11 D4 P4 7 x 3 03.06.11 None B T75 
PDAC 20.12.10 D5 P5 7 x 4 21.06.11 None A T75 
CP 25.01.11 D9 P2 7 x 5 10.05.11 None A T75 
CP 25.01.11 D6 P3 7 x 7 10.05.11 None A T75 
PDAC 19.01.11 D12 P3 8 x 1 07.05.11 None B T75 
CP 25.01.11 D14 P3 8 x 2 07.05.11 None C T75 
CP 25.01.11 D3 P6 8 x 3 25.06.11 None B T75 
PDAC 28.01.11 D10 P2 8 x 4 21.06.11 None B T75 
PDAC 20.12.10 D7 P3 8 x 5 10.05.11 None A T75 
CP 07.02.11 D21 P4 8 x 6 14.05.11 None A T75 
CP 07.02.11 D16 P2 8 x 7 10.05.11 None A T25 
CP 07.02.11 D21 P3 9 x 1 07.05.11 None B T75 
CP 25.01.11 D6 P2 9 x 2 07.05.11 None A T25 
PDAC 20.12.10 D9 P1 9 x 3 03.06.11 None A T75 
PDAC 19.01.11 D12 P5 9 x 4 21.06.11 None C T75 
CP 07.02.11 D19 P2 9 x 5 10.05.11 None A T25 
Ampul 10.02.11 D7 P2 9 x 7 10.05.11 None A T25 
CP 07.02.11 D21 P3 5 x 2 - None - - 
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CP 25.01.11 D14 P5 5 x 6 01.07.11 none C T75 
PDAC 28.01.11 D17 P1 7 x 6 04.07.11 none A T75 
PDAC 28.01.11 D4 P8 2 x 3 01.07.11 none B T75 
CP 07.02.11 D9 P3 4 x 5 04.07.11 none A T75 
PDAC 20.12.10 D5 P5 9 x 6 10.07.11 none A T75 
PDAC 20.12.10 D5 P4 3 x 8 10.07.11 none A  T75 
Table 5.1 Details of primary cultured cells stored in freezer 2 of the GCLP biobank. 
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5.1 Discussion 
 
Two decades ago the pancreatic stellate cell was identified as the cell type predominantly 
responsible for the ‘desmoplastic reaction’ 123;128.  Since then, the number of PubMed cited 
reports investigating these cells has grown exponentially.  Pancreatic stellate cells exhibit a 
great deal of interaction with cancer cells in vitro and in vivo. This feature, along with their 
contribution to the stromal reaction, has led to this cell type being proposed fundamental to 
pancreatic cancer progression 
36;49
.     
As a result of the work described in this thesis, there are now approximately eighty vials of 
primary cultured cells that have been cryopreserved in Dr Costello’s laboratory.    
Characterisation of these primary cells has revealed three distinct cell types.  Whilst it is 
highly likely that one of these three cell types represents the pancreatic stellate cell, various 
difficulties encountered during characterisation meant that this was unconfirmed.  According 
to the light microscopy and immunofluorescence data, which is discussed in more detail 
below, the cells with the Type A morphology (See Section 4.4) are the most likely candidates 
to be stellate cells.  They displayed positive expression of alpha SMA, one of the four stellate 
cell markers.  GFAP expression in these cells was also positive, along with negative or less 
intense isotype stains.  However, the experiments lacked a control cell to stain negatively for 
GFAP (See Section 5.1.2.1).  Hence, unfortunately it could not be stated with complete 
certainty that these primary cells do exhibit the GFAP protein.     
Other than stellate cells, the primary cultured cells may instead represent another pancreatic 
stromal cell type, such as a cancer-associated fibroblast or myofibroblast.  Either way, once 
fully characterised these primary cells can be utilised in experiments in Dr Costello’s 
laboratory, as an adjunct to the epithelial cancer cell lines that are frequently used for 
pancreatic cancer research.   
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5.1.1 Isolation and culture of primary cells 
 
The protocols for pancreatic stellate cell culture (See Material and Methods Section 3.0 to 
3.5) were kindly shared by Dr Phoebe Phillips, an internationally recognised expert in this 
field.  Her colleagues, led by Professor Apte were amongst the first researchers in the world 
to isolate stellate cells from the pancreas 
43;123
.  It proved necessary to adapt the methods in 
order to suit research practices here at the Royal Liverpool University Hospital (See Section 
4.1).  Measures for collecting pancreas samples were already in place.  These were performed 
to GCLP standards, thus limiting inter-sample variation attributed to inconsistent collection 
or processing methods.  Having adjusted standard operating procedures (SOP) and 
information management tools (LIMS), all of the necessary procedures were in place to 
collect tissue samples for the purposes of PSC culture, and to cryopreserve cultured cells 
within the GCLP facility.   
As explained in section 4.1.1, Dr Phillips’ protocols were refined to cater for the differences 
in the way surgical samples are collected between our two institutions.  The main problem 
encountered here was the diversion of samples from Theatre to Pathology immediately after 
resection, due to diagnostic purposes.  Hence for reasons beyond my control, precious time 
was being lost transporting the specimen back and forth, thus delaying its passage into 
culture.  Despite these obstacles, increased liaison with pathologists, surgeons and theatre 
staff ensured this inevitable time period in transport was minimised.   
Additional problems I encountered related to the timing of ‘explant’ removal from the culture 
dish and passaging or subculturing of cells. I quickly deduced that the primary cells I had 
plated in culture exhibited poor tolerability to many types of cell dissociation agent.  
Literature searches relating to PSC culture methods on Medline unfortunately yielded only a 
few resources, none of which included detailed protocols for their explant culture 
89;124;125;128
.   
Many of the early primary cell cultures perished for the reasons mentioned above.  Section 
4.1.2 describes the problems associated with fungal contamination, which was exacerbated by 
the use of 6-well plates, where the infection could potentially spread between the wells 
leading to the loss of all the cells from a patient sample.  This is the reason why 40 mm 
diameter dishes were utilised in later cultures.  In my experience fungal contamination was 
best avoided by removing tissue once cell proliferation had ceased for more than 2 weeks.  
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Necrotic tissue left in the well was perhaps the reason for contamination.  Furthermore, the  
fact that the cells had ceased to proliferate, was a possible indication that the tissue was no 
longer viable and had stopped providing the cells with growth factors, although I have no 
formal proof that this is the case.   
Having experienced additional difficulties with the timing of cell passage, I concluded that 
the primary cells could not proliferate and remain viable in a T25 flask, unless they were 
extracted from a 40mm dish that was more than 50% confluent.  This was perhaps due to the 
fact that the cells needed to be plated at a sufficiently high density to avail of paracrine 
stimulation that would facilitate growth in the new flask. Again, this was an observation I 
made through trial and error, and not one that I specifically set out to test.  
Finally, passaging these cells, as eluded to above, was initially problematic.  Eventually, 
having trialled a number of different cell dissociation reagents, a relatively weak form of 
trypsin reagent was purchased (see section 4.1.3) which was well tolerated by the primary 
cells.  At this stage in my research, having acquired more experience in the primary culture 
and passage of these cells, I was in a position to devote greater amounts of time to 
characterising them.  
  
 
5.1.2 Characterisation of primary cultured cells. 
 
Early primary cultures of cells were examined with light microscopy at 10x, 20x, and 40x 
magnifications.  Clear differences in morphology were observed between cells derived from 
the various dishes of the same patient sample (See Section 4.3).  There was some confusion 
as to whether these differences in morphology represented alternative cell types, such as 
fibroblasts or myofibroblasts, or rather corresponded to variations in cell behaviour e.g. 
recent adherence, apoptosis, or senescence (See Section 4.3 Figures 4.5 and 4.6).   
Therefore, cells were characterised for the detection of the four PSC markers: GFAP, desmin, 
alpha SMA and vimentin.  Dr Phillips’ protocols recommended the use of 
immunofluorescence staining for characterisation, and this staining method was also used by 
other research groups who have previously characterised PSCs 
89;124;125
.  Prior to beginning 
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characterisation, we received an immortalised pancreatic stellate cell line (RLT-PSC) 
89
 as a 
kind gift from Dr Ralf Jesenofsky, University of Heidelberg, to use as positive control cell in 
our experiments.  Several epithelial cancer cell lines were being cultured in Dr Costello’s 
laboratory and were utilised as potential negative cell controls. 
 
5.1.2.1 The search for a negative control cell 
 
As shown in Section 4.4.1, MiaPaCa-2 cells unexpectedly stained positively for GFAP 
(Figure 4.9C).  The rabbit isotype control stained negatively in these cells (Figure 4.8D), 
suggesting that GFAP antibody binding was specific.  Despite this, certain precautionary 
measures were taken to reduce the chance of non-specific binding in subsequent IF 
experiments.  For instance, in Section 4.4.2, the secondary antibodies were increased in 
dilution from 1:100 to 1:400.  A high concentration of secondary antibody such as 1:100 
could have caused non-specific binding in the first experiment.  In addition, different types of 
secondary antibody were used in Section 4.4.2 to ensure that none of the previous antibodies 
were faulty.     
In Section 4.4.2 positive fluorescence was again observed in the supposed negative control 
cell.  This time the MiaPaCa-2 cells had been stained for desmin and vimentin (Section 4.4.2 
Figure 5.1).  However, the results were discounted following the analysis of the rabbit isotype 
images.  Bright fluorescence was observed in these images thus indicating that non-specific 
binding was taking place (Figure 5.1).  
In section 4.4.3 MiaPaCa-2 cells were replaced with another cancer cell line named Panc-1 
cells.  Other changes included a variation of the blocking method in order to reduce the 
chances of background staining, and a reduction in the concentration of secondary antibody 
from 1:400 to 1:1000.  All of these changes were made in an attempt to achieve a negative 
stain in the Panc-1 cancer cells.  Furthermore, another set of GFAP and desmin antibodies 
were purchased from DAKO, the reason for this being that the pattern of staining in the 
MiaPaCa-2 cells in previous experiments could have been attributed to the low specificity of 
the primary antibodies from Abcam.   
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Unfortunately, the Panc-1 cells did stain positively for GFAP with the new antibody from 
DAKO (Section 4.4.3 Figure 5.2), thus probably ruling out primary antibody non-specificity 
as the cause of these cells expressing stellate cell markers.  No desmin expression was 
detected in PDAC 20.12.10 dish 5 passage 4, CP 25.01.11 dish 8 passage 2, RLT-PSC, or 
Panc-1 cells, perhaps because the antibody was used at too high a dilution (1:200, 1:500).  
Secondary antibody was also used independently to stain these four cell types to discover any 
non-specific binding (Figure 5.3).  A very faint red fluorescence was noticed in all of these 
images, indicating that the cy3 antibody was giving rise to a weak signal, despite the absence 
of primary antibody.  However, this is unlikely to be the reason for the more intense red 
staining observed in the cancer cells, as it is very low in intensity compared to the red stain 
observed in those images (Section 4.4.1 Figure 4.9 and Section 4.4.2 Figure 5.1). 
Thus far, MiaPaCa-2 and Panc-1 cancer cells had both expressed mesenchymal markers 
which was an unexpected finding (Sections 4.4.1 to 4.4.3).  Therefore, a literature search was 
performed in order to explore whether this characteristic of cancer cell lines had been 
reported elsewhere.  In a recent study, Collisson et al 
3
 described different subtypes of PDAC.  
They found that both Panc-1 and MiaPaca-2 cells have what they termed a ‘quasi-
mesenchymal’ phenotype (Figure 6.0), and expressed some mesenchymal markers.  These 
findings provided an explanation for the results observed in the first three IF characterisation 
experiments described above.  Collisson et al 
3
 also labelled Suit-2 cancer cells as having a 
‘classical’ phenotype, meaning that they do not express mesenchymal markers.  Hence, Suit-
2 cancer cells were subsequently trialled as a negative control cell in Section 4.4.5.    
 
 
 
 
Figure 6.0 Collisson et al 
3
 
reported subtypes of PDAC.  
Panc-1 and MiaPaca-2 cells have 
a QM (quasimesenchymal) 
phenotype. 
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Surprisingly, the Suit-2 cells also exhibited mesenchymal markers.  Hence, the data from 
Collisson et al 
3
 did not correlate with the results in this thesis.  The only plausible 
explanation for these results is that the Suit-2 cells in our laboratory might be contaminated 
with a different type of cancer cell line.  Ideally, this experiment would be repeated after 
rigorous genotyping analysis of the Suit-2 cells in order to validate their identity.   
A different study conducted by Arumugam and colleagues 
129
 discussed the occurrence of 
EMT in pancreatic cancer cell lines cultured in vitro.  They later demonstrated that both 
MiaPaCa-2 cells and Panc-1 cells were able to express vimentin after several years in culture.  
A third study by Zhang and colleagues 
130
 revealed that breast cancer cell lines showed 
neuronal marker expression in addition to their usual epithelial markers.  Hence, the 
expression of mesenchymal markers in MiaPaCa-2 and Panc-1 cells has been observed by 
others.  From these findings, and the negative results of the secondary antibody only stain 
(Section 4.4.3 Figure 5.2), it is probable that nonspecific binding is not taking place, and that 
the methods and reagents currently being used for blocking and staining are working 
sufficiently. 
However, there still remains the unexplained finding of intense staining displayed by the 
rabbit isotype (Section 4.4.2 Figure 5.1) which initially suggested that non-specific binding 
had taken place.  As displayed in Section 4.4.3 Figure 5.2, both rabbit and mouse isotypes 
were used at a dilution of 1:200, although only the rabbit isotype was positively stained.  In 
fact, the rabbit isotype is consistently staining positive throughout the IF stains (Figure 5.1, 
5.2, 5.5), whilst the mouse isotype has been negative.  This could indicate a problem with the 
rabbit isotype control antibody.  Therefore, an alternative rabbit isotype should be purchased 
for future experiments, or the mouse isotype should be utilised where possible. 
 
 
5.1.2.2 GFAP, desmin, and vimentin expression 
 
Having established that antibodies were seemingly working effectively and binding 
specifically despite the existence of positive staining in the cancer cell lines, the other cells 
could now be analysed for their expression of GFAP, desmin, and vimentin. 
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The Type A morphology cells, RLT-PSCs, MiaPaCa-2, and Panc-1 cells all demonstrated 
expression of GFAP (See Sections 4.4.1, 4.4.3, and 4.4.5).  These cells were also treated with 
an isotype control antibody, which stained either negatively, or less intensely than the GFAP 
antibody.  Hence, this was an indication that non-specific binding was not taking place.  
Furthermore, two different GFAP antibodies were utilised successfully in these experiments 
to ensure that neither of the primary antibodies were binding non-specifically. 
Desmin expression was assessed in sections 4.4.2 to 4.4.4.  Positive fluorescence for desmin 
was detected in section 4.4.2, although this was associated with bright staining for the rabbit 
isotype control antibody.  Once again, I am unsure whether this was non-specific binding 
associated with the desmin antibody, or there was a problem with the rabbit isotype antibody 
which has repeatedly stained positively under different experimental conditions as described 
above.  A desmin antibody from a different provider (DAKO) was utilised in section 4.4.3, 
though the staining of all cells was negative at dilutions of 1:200 and 1:500.  Hence, in 
section 4.4.4 this desmin antibody was reapplied at a dilution of 1:50, which demonstrated 
very weak expression of desmin in the primary cells (Type A morphology).  The BXPC3 
cancer cells did not show desmin expression, and the mouse isotype was negative for the 
primary cells, thus ruling out non-specific binding.  Therefore, in conclusion there possibly 
was a some degree of desmin expression, yet this was of a low intensity and it is debatable as 
to whether it should be considered as positive or negative expression.  A similar result was 
produced for the two different samples of Type A morphology cells.   
Vimentin expression was assessed in Section 4.4.2.  This was positive in two samples of 
Type A morphology cells and in the MiaPaCa-2 cells.  However, no goat isotype antibody 
was utilised and so one cannot be sure whether this fluorescence was specific to vimentin 
expression.  
 
5.1.2.3 Alpha SMA expression 
  
As expected, the MiaPaCa-2, Panc-1, BXPC3, and Suit-2 cancer cell lines all lacked 
expression of the alpha SMA protein.  Surprisingly, the immortalised pancreatic stellate cell 
line (RLT-PSC) also stained negatively for alpha SMA (Section 4.4.1 Figure 4.9D).  This is 
despite a report from Jesnowski et al 
89
 displaying fluorescent images of these cells with 
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positive expression.  This paper was published in 2005.  Perhaps these cells have 
differentiated in some way during this time or due to conditions in culture in our laboratory in 
Liverpool, resulting in absent expression of this cytoskeletal protein.  Hence, no positive 
control cell was available to represent alpha SMA expression.  Despite this, the distinctive 
strand-like staining (Section 4.4.1 Figure 4.9A), coupled with the lack of expression in the 
cancer cell lines (Section 4.4.1 Figure 4.9C), meant that the positive staining was unlikely to 
represent non-specific binding.   
As shown in Section 4.4.1 Figure 4.9B, some of the PDAC 18.10.10 well passage 2 cells 
(type A) did not exhibit alpha SMA expression.  In fact, during this experiment only around 
20% of the cells displayed this protein.  Similar findings were made in section 4.4.3 when the 
PDAC 20.12.10 dish 5 passage 3 cells (type A) were stained.  Bachem and colleagues 
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have successfully cultured human pancreatic stellate cells.  They reported that the proportion 
of their cells exhibiting alpha SMA stain is more than 70% per flask.   
This low proportion of alpha SMA expression amongst ‘type A’ morphology cells was not a 
universal finding however.  For example, PDAC 28.01.11 Dish 7 passage 4 cells (Section 
4.4.6), and PDAC 13.12.10 well 9 passage 2 cells together with CP 07.02.11 dish 7 passage 2 
cells (Section 4.4.4) were stained with alpha SMA at various dilutions.  More than 90% of the 
cells exhibited positive expression in these three samples of Type A morphology primary 
cells. 
Therefore, the low quantity of cells expressing alpha SMA in some of the cell samples may 
be due to contamination with non alpha SMA expressing cells, such as inactivated fibroblasts 
or myofibroblasts.  In fact Bachem at el 
128
 also reported that the most commonly observed 
contaminating cells in their primary cultures were non alpha SMA expressing myofibroblasts. 
Alternatively, the low quantity of cells expressing alpha SMA in some of the cell samples 
may be due to the variable dilution of the alpha SMA antibody between experiments.  Of the 
samples mentioned above, the PDAC 28.01.11 dish 7 passage 4 cells were stained at 1:400 
and 1:200 (Section 4.4.6 Figure 5.6), and the PDAC 13.12.10 well 9 passage 2 cells and CP 
07.02.11 dish 7 passage 2 cells at 1:100 (Section 4.4.4 Figure 5.4).  These three samples 
displayed greater than 90% positive expression for alpha SMA.  Conversely, the PDAC 
18.10.10 well 3 passage 2 (Section 4.4.1 Figure 4.9), and PDAC 20.12.10 dish 5 passage 2 
cells (Section 4.4.3 Figure 5.2) which were both 20% positive, were stained at 1:500.  It 
cannot be ruled out that this small difference in antibody dilution caused the large increase in 
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the proportion of antigen expression detected, and this should be tested formally in future 
work.     
The alpha SMA protein was also exhibited by ‘type B’ and ‘type C’ morphology cells 
(Sections 4.4.3, 4.4.6, and Section 4.4.5 respectively).  Less than 5% of the PDAC 28.01.11 
dish 4 passage 5 cells (Type B) displayed alpha SMA expression at dilutions of both 1:400 or 
1:200 (Section 4.4.6 Figure 5.6).  Interestingly, over 90% of the cells that were exposed to 
TGFβ treatment (Material and Methods Section 3.7.1) displayed expression of alpha SMA 
(1:200) afterwards.  The fact that these ‘type B’ morphology cells began to express alpha 
SMA when exposed to TGFβ, coupled with their lack of GFAP expression, could indicate 
that they are inactivated fibroblasts that transformed into an activated state by exposure to 
TGFβ. 
PDAC 19.01.11 dish 12 passage 3 cells, which had the type C morphology (Section 4.3 
Figure 4.7) were also stained with alpha SMA and over 50% of the cells showed positive 
expression (Section 4.4.5 Figure 5.5).  However, as mentioned above, these cells lacked 
GFAP and desmin expression which implies that they cannot be activated PSCs.     
Due to the pure populations of alpha SMA-positive cells found in the PDAC 28.01.11 dish 7 
passage 4 flask (90%), along with the myofibroblast-like appearance of the cells (type A 
morphology), these are likely to be either activated stellate cells or cancer-associated 
myofibroblasts.  If this data is considered along with the positive expression of GFAP, this 
suggests that these ‘type A’ morphology cells are more likely to represent activated PSCs 
than myofibroblasts.   
 
5.1.2.4 Conclusions and further characterisation  
 
There is solid evidence that the primary cultured cells with ‘Type A’ morphology exhibit 
alpha SMA protein expression.  Corresponding negative isotype stains signified that antibody 
binding was specific.  Furthermore, all of the other cell types failed to exhibit this marker.   
No negative control cell was established for GFAP, desmin or vimentin expression.  
However, there was convincing evidence for positive GFAP expression in the primary cells 
due to a combination of positive GFAP antibody stains and negative or weak isotype stains.  
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These results were corroborated in two separate experiments (See Sections 4.4.1 and 4.4.3).  
Despite this, the lack of a negative control cell means that one cannot say with absolute 
certainty that the primary cells do express the GFAP protein.    
Desmin expression in these cells was unconvincing and remains to be proven.  Due to time 
restrictions, desmin expression was only measured on one occasion at the optimal dilution for 
the antibody.  Thus, ideally this experiment would be repeated to reveal whether the ‘type A’ 
morphology cells exhibit the desmin protein.  Vimentin expression has been shown to be 
positive, although the lack of an isotype control means that this expression could have been a 
result of non-specific binding.    
Further characterisation experiments should incorporate the use of other cell lines to act as 
control cells, including fibroblasts or smooth muscle cells to represent negative controls.  As 
mentioned in Section 5.1.2.1 several studies suggest cancer cells are able to express 
mesenchymal markers, thus concurring with the findings in this thesis.  Moreover, an 
alternative immortalised pancreatic stellate cell line to ‘RLT-PSC’ should be utilised as a 
positive cell control in subsequent experiments, for the reason that the ‘RLT-PSC’ cell line 
failed to exhibit any alpha SMA or desmin expression.     
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5.1.3 Evaluation of microRNA expression in primary cultured cells 
 
A preliminary investigation was undertaken into the regulation of miRNA-29 in primary 
cultured cells derived from two patients (Type A morphology) and the RLT-PSC cell line.  
As mentioned earlier, cells with the type A morphology may possibly comprise pancreatic 
stellate cells in view of their positive expression of alpha SMA and GFAP in previous 
experiments (See Section 3). 
The idea to investigate the aforementioned particular family of microRNAs was gleaned from 
a recent report into liver fibrosis 
131
.  The authors found levels of miRNA-29 to be 
significantly raised in HSCs compared to other resident liver cells.  Exposure of these cells to 
TGFβ elicited a significant reduction in their miRNA-29 expression.  Up-regulation of this 
miRNA was also associated with a reduction in the expression of several ECM collagen 
genes.   
PSCs and HSCs display an almost identical gene expression profile which is 99% similar at 
the mRNA level, and there has also been speculation of whether these cells could share a 
common origin in the bone marrow 
60
.  Therefore, it would be interesting to elucidate 
whether the same mechanisms of miRNA regulation highlighted by the study above are also 
being mediated in our cells. 
Eventually, we plan to analyse the expression of all known microRNAs in both disease 
associated and quiescent pancreatic stellate cells.   However, with the recent publication of 
this report into liver fibrosis, we took the opportunity to take a preliminary examination of 
microRNA expression in our primary cells, starting with the miRNA-29 family. 
Two primary cultured cell samples, one derived from a patient with PDAC, the other from a 
patient with CP were utilised in these experiments, along with the immortalised pancreatic 
stellate cell line (RLT-PSC).  As explained in the Material and Methods Section 3.7.1, some 
of the cells from each of these samples were exposed to TGFβ, and others were left untreated 
thus resulting in six different samples from which RNA was purified. 
Unfortunately, the results of the preliminary experiment shown here were rather inconclusive.  
Despite cDNA samples being quantified using a nanodrop spectrophotometer beforehand 
(See Section 4.5.3.1 Table 4.5), the loaded cDNA concentration varied between the different 
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samples (Figure 5.9).  These variations were revealed from the use of an endogenously 
expressed RNA molecule named RNU6B, which acted as the PCR control primer.  RNU6B is 
a widely used endogenous reference RNA in many miRNA quantification studies because of 
its small size (45 nt). 
Several calculations were performed using the Cp values for the control primer and the 
miRNA primers, in an attempt to normalise the cDNA loading between samples (Tables 4.8, 
4.9, and 5.0).  Following these estimates, little difference in the levels of miRNA-29a and c 
between untreated and TGF-beta treated cells could be deduced.  The only finding that 
showed promise was the apparent downregulation of miRNA-29b in the ‘CP’ primary cells 
treated with TGFβ (Table 4.9). Here the Cp value for the TGFβ treated cells was almost one 
cycle higher than in the untreated cells.  However, the downregulation of this miRNA was 
not corroborated in any of the other cell samples.   
  
Clearly, solid conclusions cannot be drawn from these results because the normalisation 
calculations that were carried out were only an estimate.  The experiment would have to be 
repeated, this time ensuring that cDNA is loaded equally between the different samples.  
Furthermore, the real-time PCR data would benefit from the use of another primer control, in 
addition to RNU6B, just in case this control is actually being regulated under the 
experimental conditions. 
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5.2 Prospects for Future Study 
 
We propose to analyse the expression of all known microRNAs in human pancreatic stellate 
cells.  Apart from utilising disease associated stellate cells, attempts will also be made to 
culture quiescent cells from the normal pancreas to provide a control cell in the forthcoming 
experiments.   
The stocks of primary cultured cells in our laboratory which were isolated and characterised 
in this thesis are likely to be stellate cells, but require further characterisation before they can 
be utilised in such microRNA investigations. 
The analysis of microRNAs will be carried out using an array-based approach, which will 
highlight significant microRNA targets that will subsequently be validated using techniques 
such as quantitative real-time PCR. 
MicroRNAs are implicated in a whole host of cellular processes including the epigenetic 
regulation of cancer related genes 
108
.  Exploration of identified targets in pancreatic stellate 
cells should provide more insight into the behaviour of these cells.  More understanding is 
required of what mediates the transformation of PSCs from their quiescent to an activated 
state, and whether this process can be halted or even reversed. 
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